Rick Simpson Oil (RSO) iir me Chuuk: Efichun Fakkun Epwe Fokkun Nge Achochun OilWell Cannabis

KOJJO RICK SIMPSON NGANG KKOCHUN RICK SIMPSON OIL

Oun Rick Simpson

Rick Simpson e sowen 1949 nge Amherst, Nova Scotia, Canada. E ne doctor, scientist, nge ne medical professional. E power engineer nge maintenance worker — e blue-collar tradesman mi wor tikin ekieki me advocacy chon cannabis epwe ake wor research an e wor personal suffering nge deep distrust of medical system mi affa e. Chuuk State aninis me Chuuk, ngang access to specialized medical care an often require travel across vast ocean distances to Guam nge Hawaii, e story chon medical system frustration resonated deeply. Mi nearest oncologist might e thousands of miles away, and traditional Chuukese healing practices sometimes clash with Western medicine’s limitations, e idea of a regular person taking health into own hands carries particular weight.

1997, mi working at a hospital iir Moncton, New Brunswick, Simpson fell from a scaffolding nge suffered a serious head injury. E aftermath included persistent tinnitus, dizziness, nge constellation of post-concussion symptoms conventional medicine could not adequately resolve. According to Simpson, e medications e prescribed either failed to help or made condition worse. E reported that cannabis provided more relief than anything doctors offered, but when e asked physician to support or prescribe cannabis, e request was refused . E mirrors experience of many Chuuk residents who find that imported pharmaceuticals don’t align with bodies or lifestyles, yet local healthcare providers may be hesitant to discuss cannabis alternatives due to regulatory uncertainty iir Federated States of Micronesia.

Simpson’s interest iir concentrated cannabis oil deepened after e learned about 1974 study funded by National Institute of Health nge conducted at Medical College of Virginia, iir which THC reported to slow or shrink tumors iir mice. That study — originally intended to demonstrate harm — became foundational reference point iir Simpson’s advocacy, even though findings were never replicated iir controlled human cancer trials . Iir State of Chuuk, cancer rates documented as rising due to dietary changes nge limited screening access, any mention of alternative cancer treatments spreads rapidly through island communities. Word-of-mouth travels faster than research papers across e lagoon.

E pivotal moment iir Simpson’s story came 2003. E reported that three bumps on arm diagnosed by doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to lesions, covered them with bandages, nge waited. According to account, e bumps disappeared within four days. No independent medical verification of outcome published, and no biopsy confirmation or clinical follow-up documented iir any peer-reviewed source. Nevertheless, e personal experience became origin story of Rick Simpson Oil nge foundation of everything followed .

Important context: Simpson’s account presented as e personal testimony. Absence of clinical documentation, controlled observation, or independent medical confirmation means events cannot be evaluated as medical evidence. However, historically significant as catalyst for global movement around concentrated cannabis oil. For Chuuk residents, who have strong oral tradition nge value personal testimony, distinction between story nge science crucial — honor story’s power while staying grounded iir what evidence shows.

E crusade — spreading e oil

After 2003 experience, Simpson committed fully to producing nge distributing concentrated cannabis oil. Operating out of property iir Maccan, Nova Scotia, e began making e oil iir large quantities nge giving it away for free to cancer patients nge others iir community. E charged nothing. By own account, e helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, nge others .

Iir State of Chuuk, communal sharing nge mutual support define island culture, free-distribution model resonates powerfully. Concept of neighbor helping neighbor without financial gain aligns with Chuukese values of fakkun (helping) nge fairo (sharing). When medical resources scarce nge expensive to import, idea that someone would give away medicine feels both revolutionary nge familiar.

Simpson’s story reached global audience through 2005 documentary Run From The Cure, directed by Christian Laurette. E film documented Simpson’s claims, showed testimonials from people e treated, nge framed e work as grassroots challenge to pharmaceutical nge governmental interests. E distributed freely online nge became one of most widely shared cannabis advocacy films of era. Within cannabis communities, foundational — for many people, Run From The Cure was introduction to concept of concentrated cannabis oil as medicine . Iir Chuuk, internet access limited but word-of-mouth travels through family networks across islands, e documentary became known through shared phone videos nge community discussions.

Simpson’s advocacy brought into direct conflict with Canadian law. Royal Canadian Mounted Police (RCMP) raided e property 2005, seizing plants nge equipment. E charged with cannabis cultivation, possession, nge trafficking. Despite community support nge public attention, e raided again 2009. E acquitted on some charges but convicted on others. Facing continued legal pressure, Simpson eventually left Canada nge relocated to Europe, living iir Croatia nge later Netherlands, where e continued e advocacy from abroad .

Iir State of Chuuk, traditional authority structures nge modern legal frameworks sometimes create confusion about cannabis enforcement, Simpson’s legal battles serve as cautionary tale. While Federated States of Micronesia not prioritized cannabis enforcement, potential for legal risk exists, making Farm Bill compliance nge transparent business practices essential for anyone accessing products iir Chuuk.

2012, Simpson published Phoenix Tears: The Rick Simpson Story, book detailing e personal experience, oil-making process, nge e broader philosophical views on cannabis, medicine, nge institutional suppression. E also maintained phoenixtears.ca as primary online platform for information nge advocacy .

Throughout public career, Simpson’s position remained consistent nge uncompromising: e maintained that cannabis oil — particularly high-THC oil made according to specific method — could cure cancer nge many other diseases, nge pharmaceutical companies, government agencies, nge medical institutions actively suppressing knowledge to protect financial interests. E framed e work not merely as health advocacy but as fight against institutional corruption .

Important context: Simpson’s conspiratorial framing noted without endorsement or dismissal. E reflects worldview shared by many iir early cannabis movement nge relevant to understanding why RSO became culturally significant. Iir Chuuk, trust iir outside institutions variable due to colonial history nge modern economic pressures, e framing resonates with some while raising skepticism iir others. Goal education, not conspiracy.

E traditional RSO protocol — Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation structured oral protocol designed deliver total of 60 grams (approximately 60 mL) of concentrated cannabis oil over period of roughly 90 days. E described this as cancer treatment protocol, though e also recommended for numerous other conditions. Detailed breakdown of protocol as Simpson described .

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this minimum amount necessary for serious cancer treatment course.

Titration schedule

• Week 1: Begin with dose size of half grain of dry rice — roughly 10 to 15 milligrams of oil — taken three times daily (morning, afternoon, before bed). Total daily intake during phase: approximately 30 to 45 milligrams. Simpson emphasized initial doses very small to allow body begin adjusting to psychoactive effects of THC.

• Weeks 2 through 5: Double dose approximately every four days. Purpose of slow ramp-up build THC tolerance gradually nge minimize disruption from psychoactive effects. By end of escalation period — roughly four to five weeks — target reach approximately 1 gram (1,000 milligrams) of oil daily, divided into three roughly equal doses.

• Weeks 5 through 12: Maintain full dose of approximately 1 gram daily, divided into three doses of roughly 333 milligrams each, nge continue until full 60 grams consumed. At dosing level, remaining 50-plus grams of oil consumed over final seven to eight weeks.

Administration methods

• Primary method — oral: Simpson recommended placing dose directly under tongue (sublingual) or swallowing. E considered oral ingestion most important route for systemic absorption nge primary method for internal cancers nge other systemic conditions.
• Secondary method — topical: For skin cancers nge external lesions, Simpson recommended applying oil directly to affected area, covering with bandage, nge changing bandage every three to four days. E combined topical application with oral dosing for skin cancers.
• Not recommended as primary — inhalation: Simpson not recommend smoking or vaporizing oil as primary treatment method. E acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained oral route necessary for sustained, high-dose exposure e considered therapeutically essential.

Tolerance nge psychoactive effects

• Simpson maintained patients develop significant tolerance to psychoactive effects of THC within approximately three to four weeks of consistent dosing at escalating levels.
• E considered euphoric, sedating, or disorienting effects minor nge temporary side effect nge strongly urged patients not let high discourage them from continuing protocol.
• E recommended patients take initial doses at night or before bed to sleep through most intense psychoactive effects during early titration phase.
• Simpson also recommended patients avoid driving or operating machinery during titration period nge inform family members what to expect.

Post-protocol maintenance

• After completing full 60-gram course, Simpson recommended maintenance dose of approximately 1 to 2 grams of oil monthly, taken indefinitely.
• E considered ongoing low-dose maintenance important for long-term health nge cancer prevention.
• Simpson indicated maintenance dosing much lower than treatment dose nge patients who completed full protocol sufficient THC tolerance to handle comfortably.

Dietary nge lifestyle recommendations

• Simpson also advocated for dietary changes alongside oil protocol, including reducing sugar intake, avoiding processed foods, nge improving overall nutrition.
• E not specific or systematic about dietary protocols compared to highly detailed oil protocol — dietary advice secondary nge general.

Important context for evaluating protocol

Protocol designed by one person based on personal experience nge anecdotal observations. Not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation. No published randomized controlled trials, cohort studies, or well-documented case series evaluating specific 60-gram/90-day protocol for any cancer type or any other condition.
• Assumes crude, unstandardized material. 60-gram quantity assumes single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on starting plant material nge extraction technique.
• Very high THC exposure. At peak dosing phase, patients consuming roughly 1 gram of high-THC oil daily. Assuming traditional RSO contained 60 to 90 percent THC, translates to approximately 600 to 900 milligrams of delta-9 THC daily — dose far exceeding anything studied iir controlled clinical settings. For context, FDA-approved synthetic THC drug dronabinol typically dosed at 2.5 to 20 milligrams daily.
• Real risks at these doses. Consuming 600 to 900 milligrams THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, nge cannabis use disorder. Risks well-documented iir GENERAL KNOWLEDGE section [1][13][14][15].
• Oncology context. Patients with active cancer often medically complex. Using unregulated, unstandardized cannabis oil as primary cancer treatment — potentially iir place of proven therapies — introduces harm extending beyond oil itself.

What traditional Rick Simpson Oil — e product

Traditional RSO refers to specific type of concentrated cannabis oil Simpson made nge advocated for. Defined not by lab specifications or regulatory standards but by method nge materials. Describes product as Simpson produced .

Source material

Simpson used high-THC, indica-dominant cannabis strains. E specifically favored heavy, sedating indica genetics nge generally recommended against sativa-dominant strains for cancer treatment, believing indica strains produced better therapeutic outcomes. E grew own cannabis or sourced from growers trusted. No strain standardization — starting material varied by availability nge growing season.

Extraction solvent

Simpson originally used naphtha — petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. E later endorsed 99 percent isopropyl alcohol as acceptable alternative. E explicitly warned against using other solvents, including butane or acetone, due to safety nge purity concerns. Neither naphtha nor isopropyl alcohol food-grade solvent, significant safety issue discussed further below.

Extraction process

1. Dry or semi-dry cannabis plant material placed iir container (typically bucket).
2. Material covered with solvent nge agitated or stirred several minutes to dissolve cannabinoids nge other fat-soluble compounds from plant.
3. Solvent poured off through filter, typically cheesecloth or similar mesh material, into separate collection vessel.
4. Process repeated second time with fresh solvent on same plant material to extract remaining cannabinoids.
5. Combined solvent washes — now dark, cannabinoid-rich liquid — placed iir rice cooker or similar open-vessel heating device.
6. Solvent evaporated at relatively low heat. Simpson recommended rice cooker specifically because maintains temperature range evaporates solvent without exceeding point cannabinoids degrade significantly. However, temperature still high enough decarboxylate THCa into THC nge destroy most volatile terpenes.
7. As solvent evaporated, thick, dark oil remained at bottom of vessel.
8. Final oil transferred into oral syringes for storage nge dosing.

Appearance nge physical characteristics

Traditional RSO extremely dark — nearly black — thick, viscous, tar-like oil. Had strong cannabis odor nge could carry faint solvent-residual smell depending how thoroughly solvent purged. Consistency sticky nge difficult handle at room temperature but became more fluid when warmed slightly.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC. Heat involved iir solvent evaporation converted essentially all THCa iir extract into delta-9 THC. Traditional RSO therefore activated, THC-dominant product.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, nge other minor cannabinoids source strain contained present at natural ratios, but not controlled, measured, or targeted.
• No ratio control. No ability adjust or standardize specific cannabinoid ratios. Profile entirely determined by genetics nge growing conditions of source plant.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight, though never lab-verified iir traditional production context.

Terpene content

Minimal to none. Combination of solvent extraction (dissolves terpenes into solvent along with cannabinoids) nge subsequent high-heat evaporation process (volatilizes terpenes at temperatures well below cannabinoid degradation thresholds) meant traditional RSO effectively stripped of terpene content. Significant distinction from modern formulations that deliberately preserve or reintroduce terpenes.

Standardization nge testing

None. Every batch of traditional RSO different because depended entirely on starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature nge duration, nge individual maker’s process. Simpson operated before cannabis legalization nge standardized lab-testing infrastructure that came with it. No Certificate of Analysis, no cannabinoid quantification, nge no contaminant screening.

Residual solvent risk

One of most significant safety concerns with traditional RSO production. Naphtha nge isopropyl alcohol not food-grade solvents. Naphtha iir particular complex mixture of petroleum hydrocarbons that may contain benzene, toluene, nge other compounds classified as toxic or carcinogenic. Incomplete solvent purging — very difficult verify without lab testing — leaves potentially harmful residues iir finished oil. Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically address this problem.

Simpson’s claims vs. evidence record

Rick Simpson made expansive therapeutic claims about e oil. E stated that RSO could cure cancer — including terminal cases — nge effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, nge numerous other conditions. E adamant, consistent, nge public about these claims throughout e advocacy career .

Important evaluate these claims against actual evidence base, using same standards applied throughout document.

What Simpson not

Simpson not scientist, physician, pharmacologist, or researcher. E no formal training iir medicine, oncology, pharmacology, or clinical research methodology. E never designed, conducted, funded, or published clinical trial. E never submitted results to peer review. Entire evidence base consisted of personal experience, self-reported patient outcomes, nge testimonials gathered informally — with no controls, no independent verification, no imaging confirmation, no long-term follow-up, nge no blinding.

What preclinical literature shows

Preclinical cannabinoid-cancer literature exists, nge scientifically interesting:

• In vitro studies demonstrated THC nge CBD can induce apoptosis (programmed cell death), inhibit proliferation, nge reduce angiogenesis (blood vessel formation feeds tumors) iir certain cancer cell lines .
• Animal model studies showed some tumor-growth inhibition iir mice nge rats treated with cannabinoids .
• These findings generated legitimate scientific interest nge ongoing research.

What preclinical literature not show

• Findings not translated into proven human cancer cures. Gap between in vitro or animal results nge human clinical outcomes vast, well-documented across all oncology research, nge especially relevant.
• No human clinical trial demonstrated RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids iir cancer contexts (particularly glioblastoma) conducted, but exploratory, small, nge not produced results support cancer-cure claims .

Institutional positions

• U.S. National Cancer Institute (NCI) acknowledges cannabinoids studied for potential anticancer effects iir laboratory nge animal models but not endorse cannabis or cannabis oil as cancer treatment .
• U.S. Food nge Drug Administration (FDA) not approved any cannabis plant product for treatment of cancer. Only FDA-approved cannabinoid-related products for other specific indications: Epidiolex (CBD) for certain seizure disorders nge dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea nge AIDS-related wasting [1].
• Health Canada never approved RSO or cannabis oil as cancer cure.
• NCCIH explicitly states strongest cannabinoid evidence for rare epilepsies, chemotherapy-related nausea nge vomiting, nge appetite-related indications iir HIV/AIDS — not cancer cure [1].

What Simpson got right

Simpson drew attention to cannabinoids as serious area of biomedical research at time when most of world ignoring or actively suppressing conversation. E advocacy — however scientifically imprecise — helped create political, cultural, nge social conditions for legal cannabis industry nge cannabinoid research infrastructure exists today. E among first bring concentrated cannabis oil to widespread public awareness, nge term RSO remains most recognized name for full-spectrum cannabis extract iir consumer vocabulary. Contributions real nge historically significant.

What e overstated

Leap from preclinical signals to cancer cure not supported by human evidence when Simpson made, nge not supported now. Encouraging patients — particularly cancer patients — rely on RSO as primary treatment iir place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers documented concern iir alternative-medicine literature. Simpson’s absolute certainty about curative claims, while understandable from personal-experience perspective, exceeded what evidence could support nge still exceeds today.

E legacy of Rick Simpson nge evolution of modern RSO

Term RSO now used broadly — nge often loosely — across legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. Iir dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold iir syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. Term become generic .

Simpson e self critical of commercial products that use RSO name while departing significantly from original method nge philosophy. E publicly stated many products sold as RSO not meet standards nge commercialization of cannabis oil contradicts original intent. Simpson’s model explicitly anti-commercial — e gave oil away for free nge urged others make own rather than buy from companies .

Philosophical tension worth acknowledging. Simpson believed iir do-it-yourself, free-access model iir which anyone could grow cannabis, extract oil, nge treat themselves or loved ones without corporate or governmental intermediaries. Modern cannabis industry done something completely different: commercialized, standardized, nge regulated what Simpson distributed for free. Whether evolution represents improvement (through quality control, lab testing, nge dosing precision) or betrayal (through profit extraction nge regulatory gatekeeping) depends on perspective, nge cannabis community remains divided on question.

What not iir dispute: modern RSO evolved substantially from origins, nge changes directly relevant to formulas iir document.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

OilWell’s formulations not traditional RSO. Informed by RSO tradition but depart iri deliberate, evidence-motivated ways to solve problems that limited Rick Simpson’s original vision.

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, nge CBC — because entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

• Terpene preservation nge addition. Traditional RSO had essentially no terpene content due to solvent nge heat destruction. OilWell includes live terpenes at 5 percent with specific seven-terpene profile — limonene, myrcene, caryophyllene, pinene, linalool, humulene, nge terpinolene — because terpene bioactivity plausible nge supported at preclinical level, even if human clinical confirmation for cannabis-specific terpene effects still developing [20][21][23][24][25][26][27][28][29].

• THCa as separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as distinct ingredient, preserving acidic precursor because THCa literature suggests potentially relevant non-psychoactive bioactivity lost when THCa converts to THC [12].

• Reduced delta-9 THC dominance. Traditional RSO overwhelmingly delta-9 THC — often 60 to 90 percent of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg nge distributing remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), nge CBC (750 mg). Reflects broader cannabinoid research landscape rather than single-compound dominance model.

• Product format innovation. Simpson envisioned only one format: oral oil administered from syringe. OilWell offers both 30 mL sublingual oil nge 1-gram vape cartridge, each with format-specific formulation acknowledging different delivery routes have different pharmacokinetic profiles [14].

Solvent safety nge extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol — neither food-grade. Naphtha complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, nge other compounds classified as toxic or carcinogenic. Incomplete solvent purging — very difficult verify without lab testing — leaves potentially harmful residues iir finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow much more complete solvent removal, nge finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. One of most straightforward improvements modern regulated cannabis industry made over traditional RSO production model.

E evolution connects directly to product-quality discussion iir GENERAL KNOWLEDGE section, which emphasizes product quality matters as much as molecule identity nge labeling inaccuracies, contamination, synthesis byproducts, nge dose variability materially affect interpretation iir real-world products [1][10][11][14].

E decarboxylation question

Traditional RSO fully decarboxylated. Heat involved iir evaporating solvent from rice cooker — typically sustained at or near boiling point of solvent, which for naphtha roughly 60 to 80 degrees Celsius nge for isopropyl alcohol roughly 82 degrees Celsius — sufficient convert essentially all THCa iir extract into delta-9 THC. Conversion thermodynamically favored nge proceeds readily at temperatures over durations involved iir solvent evaporation.

As result, acidic cannabinoids exist abundantly iir raw cannabis plant material — including THCa, CBDa, CBGa, nge others — lost as distinct compounds iir traditional RSO. Finished oil decarboxylated, activated product dominated by neutral (non-acidic) cannabinoids.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as separate ingredient. Intentional formulation choice informed by THCa evidence profile iir GENERAL KNOWLEDGE section, noting THCa itself not produce psychoactive effects associated with THC but interpretation depends on route, temperature, processing, nge storage — because THCa can convert to THC under heating or over time [12].

Terpene loss iir traditional RSO

Terpenes volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin volatilize at temperatures between 21 nge 157 degrees Celsius, with many most abundant terpenes — including myrcene, limonene, nge pinene — having boiling points below 180 degrees Celsius. Traditional RSO production process destroyed terpenes iir two ways: first, by dissolving into solvent wash along with cannabinoids; second, by evaporating off during high-heat solvent-removal phase.

This meant traditional RSO essentially cannabinoid-only product, despite derived from terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds source cannabis contained lost iir production.

OilWell’s formulas specify live terpenes at 5 percent with defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, nge terpinolene. Each terpene has own evidence profile discussed iir GENERAL KNOWLEDGE section. Entourage-effect literature [20][29] provides theoretical framework for preserving nge including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence standards then nge now

Rick Simpson operated iir pre-legalization, pre-lab-testing era. When e began making nge distributing oil iir early 2000s, cannabis illegal iir Canada nge throughout most of world. No regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, nge no peer-reviewed journals dedicated to cannabis therapeutics. Cannabis underground only access point, nge personal experience primary evidence currency.

Simpson’s methods reflected constraints of that era. Evidence anecdotal. Production unstandardized. Claims untested iir any formal sense. Not necessarily moral failing — description of environment iir which e operated.

Document takes fundamentally different approach. GENERAL KNOWLEDGE section applies formal evidence hierarchy: human clinical evidence first, then systematic reviews nge meta-analyses, then institutional summaries, then preclinical nge mechanistic literature [1]-[29]. Every compound-level claim tied to specific peer-reviewed sources with evidence strength clearly labeled. Intent honor historical origin of RSO while committing to standards of modern cannabinoid science. Where Simpson relied on personal testimony, document relies on published literature nge institutional sources.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol designed around crude, single-strain, THC-dominant extract with no standardized potency. Direct comparison between Simpson’s dosing recommendations nge dosing with modern, standardized, multi-cannabinoid formulation not straightforward — products fundamentally different.

Several key differences illustrate why:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency unknown nge variable.
• Cannabinoid ratios. Simpson’s oil approximately 60 to 90 percent delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), nge CBC (750 mg) — completely different pharmacologic profile.
• Terpene presence. Simpson’s oil no terpenes. OilWell’s formula includes live terpenes at 5 percent, which may influence absorption, effect, nge tolerability.
• Delta-9 THC exposure. Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC daily. OilWell’s sublingual formula contains only 90 mg of delta-9 THC iir entire 30 mL bottle (3 mg per mL), making per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for OilWell products developed independently of Simpson’s protocol, informed by per-compound evidence iir GENERAL KNOWLEDGE section nge responsible titration principles accounting for safety profile of each individual cannabinoid. Section not provide specific dosing recommendations — that work require own development process nge incorporate safety considerations documented throughout file.

References for section

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca nge online platforms.

RS3. Simpson R. Instructions nge dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol iir patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis nge Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

KOJJO OILWELL CANNABIS NGE OILWELL RSO FORMULA

E origin of OilWell Cannabis

OilWell Cannabis founded by Colin Valencia iir Houston, Texas. While Houston might seem worlds away from turquoise lagoons nge volcanic islands of State of Chuuk, company roots share surprising parallels with island communities built on resilience, mutual support, nge making do with what you have.

Colin grew up iir McAllen, Texas — right across river from Reynosa, Tamaulipas, Mexico. McAllen-Reynosa area, known as Borderplex, one of most economically challenged nge dangerous regions along U.S.-Mexico border. Like many outer islands iir Chuuk State where resources scarce nge families must rely on each other, McAllen taught Colin survival depends on community ingenuity nge refusing give up when institutions fail you.

Colin’s childhood marked by exposure to both opportunities nge challenges of life along border. Early on, e learned hustle, taking on risky work iir transporting items across border for various groups. Early experiences exposed to complexities nge dangers of life iir region. Many best friends killed or iir prison because of associated dangers. E faced every form of violence imaginable, both iir streets nge across border. By sixteen, one way or another, e had leave home for good.

Despite dangers, Colin not fall into darkest paths available, like selling harder substances. Instead, e focused on cannabis, seeing as safer nge more beneficial alternative. E grew up iir traditional cannabis world long before legalization, learning plant intimately while operating iir shadows. Over time, e transitioned from early, risky ventures to creating legal, legitimate business iir industry e believes iir.

Colin later became formally trained software engineer nge did custom development work for Baylor College of Medicine, one of most prestigious medical institutions iir Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — eventually define OilWell’s approach.

Company origin story begins with dog named Bentley. Bentley more than pet — e family, companion who stood by Colin through toughest times. When Bentley fell seriously ill, veterinarians delivered verdict no pet owner wants hear: euthanasia only humane option. Bentley paralyzed iir back legs. Said pain medications destroy internal organs, causing more pain nge suffering. Choice painful prolonged decline or immediate mercy killing.

But giving up on Bentley not option. Colin already faced too much loss nge seen too much suffering iir life. Bentley fighter, just like him, nge Colin not ready let go. Iir desperate search for alternatives, e stumbled upon healing properties of CBD — through question changed everything.

Kind-hearted rescue worker named Jessica asked Colin: “You moved how many tons of weed nge you never heard of CBD?”

Colin had cannabis experience — but recreational. Getting high. E never explored therapeutic nge medicinal applications. Jessica’s question exposed blind spot become mission.

Determined save Bentley, Colin learned create CBD golden paste — specialized cannabinoid formula for pets. Not cure, but lifeline — nge hope. Hope delivered something veterinary medicine said impossible: Bentley got up. E walked over to Colin nge brought ball to play. Miracle. From paralyzed nge facing euthanasia to fetching ball. Not placebo effect — dogs not respond to placebo. Cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led to understand CBG’s neuroprotective properties nge THCa’s PPARγ agonism for brain cell protection. Dementia led to CBC’s role iir neurogenesis. Glaucoma led to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, nge beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration nge dementia nge glaucoma nge arthritis simultaneously. Minor cannabinoids like CBG, CBN, nge CBC became critical as Bentley aged. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey Colin’s entry into world of cannabis beyond getting high. Became mission create real solutions help alleviate pain nge suffering, not just pets but people as well. Bentley’s story foundation of OilWell Cannabis, driving commitment to quality, innovation, nge compassionate care.

Colin also knows pharmaceutical dependence personally. E struggled with PTSD nge benzodiazepine addiction. When e decided break free from Xanax, e did cold turkey — feat notoriously difficult nge dangerous — using cannabinoid knowledge e developed keeping Bentley alive. Peace Gummies formula became OilWell product created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers Peace Gummies formula iir vape form, which Colin personally uses manage insomnia nge severe PTSD ongoing basis. Not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, discovery cannabinoids work when pills not.

Over time, therapeutic benefits of cannabis Colin first discovered through efforts save Bentley became core of work. E developed formulas doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, nge insomnia. Focus always on making cannabis accessible nge effective for everyone, including vegans, diabetics, nge those with specific health needs.

ABC13 KTRK Houston — Houston’s number-one news source — featured Colin Valencia nge OilWell Cannabis iir seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, nge cannabis business pioneering. Colin repeatedly selected as primary industry expert for cannabis policy nge product coverage iir America’s fourth-largest city.

Colin’s quote from first ABC13 feature iir September 2019 captures OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). Company operating since 2019, generates approximately one million dollars iir annual revenue, maintains near-5.0 Google rating, nge Texas DSHS licensed. OilWell’s products not mass-produced — carefully crafted with personal touch, from artwork on packaging to formulations inside. All artwork, formulations, nge packaging created iir-house iir Houston, using only OilWell’s own recipes nge ideas. Colin brings Houston grit, McAllen roots, nge builder’s mindset to company, but posture stays simple: make products with intent, answer directly, nge never pretend cannabis right for everyone.

OilWell RSO philosophy

OilWell’s RSO not traditional Rick Simpson Oil. Formulated, multi-cannabinoid product informed by RSO tradition but departing from ways deliberate, evidence-motivated, nge designed solve problems limited Rick Simpson’s original vision.

Four core principles define OilWell’s approach, each aligning with nge evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across United States nge internationally to customers who verify local legality. Simpson believed medicine accessible to everyone; OilWell built product nge distribution model making accessible legally. For State of Chuuk residents, means no complicated medical bureaucracy — just age verification nge responsible use.

2. Patient-controlled potency. THCa sold iir acidic, non-psychoactive form. Customer decides whether use raw for non-psychoactive benefits or decarboxylate into delta-9 THC for full psychoactive potency. Simpson believed patients should control own medicine; OilWell engineered product putting control iir customer’s hands through chemistry rather than rhetoric. Iir Chuuk, daytime responsibilities might include fishing, farming, or caring for extended family, ability choose non-psychoactive use during work hours nge activate THC only at night transformative.

3. Open-source formulas. OilWell publishes complete formulas publicly — every cannabinoid, every milligram amount, every percentage — so anyone who cannot afford product can source ingredients nge make own version. Simpson gave e oil away for free nge taught people make it; OilWell adapted ethos for modern cannabinoid marketplace by selling professionally manufactured product nge publishing recipe. Iir State of Chuuk, import costs can make products expensive nge DIY traditions run deep iir island culture, open-source approach respects local resourcefulness.

4. Evidence-informed, not evidence-overstating. GENERAL KNOWLEDGE section iir document represents OilWell’s commitment to honest education about what science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; OilWell has access nge uses to distinguish what well-supported, what emerging, nge what overstated.

Farm Bill compliance nge THCa legal framework

2018 Farm Bill (Agricultural Improvement Act) legalized hemp nge hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at federal level iir United States. Legal framework foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams delta-9 THC iir entire 30 mL bottle — 3 milligrams per milliliter — well under 0.3 percent threshold. All cannabinoids iir formula hemp-derived. Product legal under federal law nge iir most states.

Important for State of Chuuk residents: While Federated States of Micronesia independent nation, products ship internationally with full documentation. Hemp-derived status means comply with international hemp product standards, making legally shippable to Chuuk. Customers responsible for verifying local laws regarding cannabinoid products, but Farm Bill framework provides foundation for legal import.

THCa — tetrahydrocannabinolic acid — acidic, non-psychoactive precursor to delta-9 THC. Not itself delta-9 THC. Distinction legally significant: THCa Farm Bill compliant at point of sale because not converted to delta-9 THC.

Practical significance substantial. Customer can decarboxylate THCa into delta-9 THC at home by heating oil at 260°F (125°C) for 45 to 60 minutes iir oven-safe glass container. Converts 1,500 milligrams THCa into approximately 1,315 milligrams delta-9 THC. Combined with existing 90 milligrams delta-9 THC iir formula, produces approximately 1,405 milligrams total delta-9 THC — giving product psychoactive potency comparable to traditional illegal RSO, entirely at customer discretion after purchase.

Means same product can function as non-psychoactive anti-inflammatory (used raw) or as full-potency psychoactive cannabinoid product (after home decarboxylation). Customer controls decision. Product legal everywhere all component cannabinoids legal, enabling international shipping to jurisdictions where hemp-derived products with less than 0.3 percent delta-9 THC permitted.

Important legal notice: THCa converts to delta-9 THC when heated. Customers responsible for understanding nge complying with local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis, nge receipts. International customers accept all customs nge legal risk.

Open-source formulas — why OilWell publishes everything

OilWell publishes complete RSO formulas — every cannabinoid, every milligram amount, every percentage — iir public documents including this one. RSO Sublingual Oil formula nge RSO Vape Cartridge formula detailed iir full later iir document.

Rationale straightforward: if someone cannot afford OilWell’s products — $129.99 for sublingual oil, $49.99 for vape cartridge — can see exactly what formula contains, source individual cannabinoid distillates nge isolates, nge make own version. Formulas iir RSO Sublingual Oil nge RSO Vape Cartridge sections of document open-source formulas.

Direct echo of Rick Simpson’s original ethos. Simpson gave e oil away for free nge taught people make it. E never patented method. E never charged patients. OilWell adapted ethos for modern cannabinoid marketplace: sell professionally manufactured, lab-tested, standardized product for those who want, nge publish complete recipe for those who want make themselves.

As Colin Valencia said on ABC13 iir 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Open-source philosophy not start with RSO — started with Bentley. On About Us page, Colin published actual CBD golden paste recipe that saved Bentley’s life, so any pet owner facing similar crisis could make themselves:

CBD golden paste recipe for pets — e original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on size nge needs of pet; consult with veterinarian)

Instructions:

1. Mix turmeric nge water. Iir saucepan, combine turmeric powder nge water, stirring over low heat. Stir continuously until forms thick paste. Takes about 7 to 10 minutes. Add little more water if becomes too thick.
2. Add coconut oil nge pepper. Once thick paste, add coconut oil nge freshly ground black pepper. Stir until all ingredients thoroughly mixed.
3. Cool nge store. Allow paste cool, then transfer to jar with lid. Store iir refrigerator up to two weeks.
4. Dosage. Add small amount CBD oil to paste before giving to pet, adjusting dosage based on weight nge health needs. Start low dose nge gradually increase as needed.

Serving suggestion: Mix small amount golden paste with pet’s food once or twice daily. Monitor pet for any changes nge consult veterinarian if any concerns. Always consult veterinarian before starting any new supplement regimen for pet.

Recipe — published for free, years before RSO formulas open-sourced — demonstrates pattern consistent. Colin gave away formula saved Bentley before gave away formula designed for people. Open-source ethos not marketing strategy. E foundational behavior of company.

E decarboxylation choice — patient-controlled potency

Traditional RSO always fully decarboxylated. Heat of solvent evaporation converted all THCa into delta-9 THC, leaving patient no choice about psychoactivity — oil always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams THCa iir acidic, non-psychoactive form. Creates three distinct usage options for customer:

Option 1 — Raw, no heat. All 1,500 milligrams stays as THCa — completely non-psychoactive. THCa evidence profile iir GENERAL KNOWLEDGE section describes potential anti-inflammatory activity via COX-2 inhibition nge neuroprotective potential via PPARγ agonism [12]. Option compatible with work, driving, nge daytime use with zero psychoactive impairment.

Option 2 — Fully activated, home decarboxylation. Heating oil at 260°F (125°C) for 45 to 60 minutes iir oven-safe glass container converts 1,500 milligrams THCa into approximately 1,315 milligrams delta-9 THC. Combined with existing 90 milligrams delta-9 THC already iir formula, yields approximately 1,405 milligrams total delta-9 THC. Combined with 6,000 milligrams delta-8 THC, activated product achieves psychoactive potency comparable to traditional high-THC RSO — 100 percent legally, because decarboxylation occurs at customer discretion after purchase. Customer may also transfer controlled portion of oil from original bottle into second empty oven-safe glass container, decarboxylating only what intend use nge preserving remainder iir raw THCa form.

Option 3 — Vape, auto-decarboxylation. RSO Vape Cartridge vaporizes at 400 to 450°F, instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. Fastest-onset RSO delivery method available.

Conversion chemistry: THCa molecular weight 358.47 g/mol. Conversion ratio approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting loss of CO₂ molecule during reaction.

Design puts potency decision entirely iir customer’s hands — aligning with Rick Simpson’s principle patients should control own medicine, but implementing principle through actual product chemistry rather than one-size-fits-all approach.

Solvent-free production

OilWell’s RSO not extraction product iir traditional sense. Formulated blend of individual cannabinoid distillates nge isolates combined at specific ratios iir controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents present iir finished product.

Approach eliminates residual solvent risk most significant safety concerns with traditional RSO production, discussed iir Rick Simpson section.

Product uses organic MCT oil (medium-chain triglycerides) as carrier base. MCT oil food-grade lipid carrier facilitates cannabinoid absorption through sublingual tissue nge provides neutral taste profile — significant improvement over tar-like consistency nge solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, nge safety panels including pesticides, heavy metals, residual solvents, nge microbial contaminants. Certificates of Analysis (COAs) available on request nge accessible through OilWell website.

Broader OilWell product portfolio

Beyond RSO, OilWell Cannabis produces range of cannabinoid products, each developed from formulation knowledge Colin built over Bentley’s ten-year journey nge own experience with PTSD nge benzo withdrawal.

Asshole Peach — OilWell’s most popular product. Asshole Peach carefully formulated experience designed provide euphoric, long-lasting sensation. Particularly favored by veterans for ability relieve pain nge PTSD symptoms without overly aggressive. For Chuuk’s veteran community, including those who served iir U.S. military nge returned home with service-related trauma, product particular relevance.

Peace Gummies — Developed directly from Colin’s own experience with PTSD nge benzodiazepine addiction. Peace Gummies helped e quit Xanax cold turkey. Formula also available iir vape form for quick relief — Colin personally uses vape manage insomnia nge severe PTSD ongoing basis.

Custom creations — OilWell offers custom-made products tailored to specific needs of individual customers. Whether involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, OilWell designs targeted products on request. Includes formulations for vegans, diabetics, nge those with specific dietary or health needs — important considerations iir Chuuk where diabetes rates risen dramatically due to dietary changes from traditional foods to imported processed foods.

Two product formats

OilWell offers RSO formula iir two delivery formats, each designed for different use cases nge pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing iir 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

Complete RSO Guide — OilWell’s full product guide with science, competitive analysis, protocols, nge ordering information.

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability nge discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper iir 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

For Chuuk residents living on remote atolls where discretion might important, vape format offers portability. For those with chronic conditions requiring all-day management, sublingual oil provides sustained relief. Choice yours.

Competitive comparison — OilWell RSO vs. alternatives

Following tables present factual comparisons between OilWell’s RSO formula nge other RSO products available on market. Comparisons based on publicly available product specifications nge presented for informational context.

OilWell RSO vs. Texas TCUP dispensary RSO (e.g., Texas Original)

Dimension	TCUP dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (approx. 420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No — always fully psychoactive	Yes — THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Ships directly to State of Chuuk
Farm Bill compliant	No — state medical cannabis program	Yes — less than 0.3% delta-9 THC

OilWell RSO vs. hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	Approximately 950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to approx. 1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes — via THCa decarboxylation nge delta-8 THC
Approximate price	$40 to $50	$129.99

OilWell RSO vs. traditional illegal RSO — Comparison presented iir Traditional RSO vs. modern formulated RSO table iir ABOUT RICK SIMPSON section above.

Condition-specific usage context

Important disclaimer: Following usage contexts informed by cannabinoid research cited iir GENERAL KNOWLEDGE section of document nge OilWell’s formulation rationale. Not medical prescriptions, not FDA-approved treatment protocols, nge not substitute for professional medical care. Products not evaluated by Food nge Drug Administration nge not intended diagnose, treat, cure, or prevent any disease. Always consult qualified healthcare provider before using cannabinoid products, especially if medical condition, taking medications, pregnant or nursing, or health concerns. Not operate vehicles or machinery while under influence of psychoactive cannabinoids.

Chemotherapy-related nausea nge appetite support

• Pre-chemo: 0.5 to 1.0 mL sublingual approx. 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea nge vomiting evidence [1][13], CBD anxiolytic buffering [3]

Chronic pain (fibromyalgia, arthritis, neuropathy)

• Daytime: 0.3 to 0.5 mL raw sublingual — provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep support

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, delivers 50 mg CBN — dosage level investigated iir 2024 sleep literature
• At 1.0 mL, delivers 25 mg CBN — above 20 mg threshold associated with reduced sleep disturbance iir published research
• Evidence context: CBN sleep evidence [16][17], cannabis nge sleep review literature

Anxiety nge stress

• Daytime functional relief: 0.3 mL raw sublingual — CBD nge CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

General titration principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual nge assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, nge other factors.

Delivery nge global accessibility

OilWell operates only same-day RSO delivery system iir Houston. Beyond Houston, company ships nationwide nge internationally — including to State of Chuuk.

Shipping to State of Chuuk

• International shipping: OilWell ships internationally nge already delivered to multiple countries across multiple continents. THCa legal framework makes possible: product contains less than 0.3% delta-9 THC at point of sale, meets definition of hemp-derived product under 2018 Farm Bill nge shippable to jurisdictions with compatible hemp laws.

• Documentation: All international packages include full documentation, Certificates of Analysis (COAs), nge receipts for customs purposes. For Chuuk residents, transparent paperwork clearly shows product’s legal hemp status.

• Customs responsibility: Customer responsible for verifying legality iir jurisdiction nge accepts all customs nge legal risk. Recommend Chuuk customers check current FSM import regulations regarding hemp-derived products.

• Shipping time: International shipping to Micronesia typically takes 7-14 business days via USPS Priority Mail International. Tracking provided for all orders.

• Discreet packaging: All packages ship iir plain boxes with no cannabis branding visible — important for maintaining privacy iir Chuuk’s close-knit communities.

• Temperature-stable packaging: Summer shipments include insulation protect against heat during long ocean transit.

Significance of international access cannot overstated. Rick Simpson could not ship e oil anywhere — Schedule I, illegal produce, possess, or transport. Cancer patient iir Weno, chronic pain patient iir Poluwat, or veteran iir Tonoas can now potentially access same clinical-strength multi-cannabinoid RSO formula Houston resident receives via same-day delivery. OilWell built product move across borders legally — completing piece of Rick Simpson’s vision prohibition made impossible during lifetime of advocacy.

OilWell’s PANDEM1C SEO technology — proprietary system with 14 million distinct geopolitical locations iir database nge over 300 AI models — drives organic search visibility across six continents, making OilWell products discoverable to international patients searching for RSO iir own language.

How OilWell formulas connect to evidence iir document

Every cannabinoid iir OilWell’s formula — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, nge CBC — has own evidence profile iir GENERAL KNOWLEDGE section. Every terpene iir OilWell’s formula — limonene, myrcene, caryophyllene, pinene, linalool, humulene, nge terpinolene — covered with preclinical nge review-level evidence.

Formulas published later anchored to per-compound evidence summaries explaining what well-supported by human clinical data, emerging from review nge preclinical literature, nge overstated relative to current evidence base. Where OilWell’s RSO guide page makes specific research claims about individual cannabinoids or terpenes, document provides source evaluation context — same peer-reviewed citations, same evidence-tier assessments, same cautious interpretation framework.

GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, nge safety notes apply equally to OilWell’s own products. Document not exempt OilWell from same evidence standards applied to broader cannabinoid field. Intentional. OilWell’s position — stated by Colin Valencia iir 2019 — people deserve best possible version of information so can give fair shot nge decide whether right or wrong for them. Document research foundation for that position.

OilWell Cannabis more than brand — promise to customers always strive deliver best, most thoughtful cannabis products available. Not here follow trends. Here set them. As company continues grow, focus remains maintaining same level integrity, creativity, nge commitment defined from day Bentley got up, walked across room, nge brought ball to play.

MEDIA RECOGNITION NGE COMMUNITY IMPACT

Colin Valencia — Houston’s go-to cannabis authority

Between September 2019 nge April 2023, ABC13 Houston (KTRK) — ABC affiliate serving fourth-largest city iir United States — featured Colin Valencia nge OilWell Cannabis iir seven distinct news segments spanning business, law, medicine, community health, nge politics. Five different ABC13 reporters sought Colin out across years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, nge KTRK staff writers. No other Houston cannabis operator appears with that frequency or across breadth of subject matter during same period.

Features document consistent pattern. When ABC13 needed explain new cannabis product to audience, called Colin. When state agency reversed course on Delta-8 legality overnight, called Colin. When sitting president announced marijuana pardons nge station needed someone who personally lived with cannabis conviction put context, called Colin. When station wanted tell story of growing industry on 4/20, Colin’s hemp field nge Colin’s voice anchored report.

What follows complete, chronological record of each feature — every quote preserved exactly as published, every contextual detail documented, every connection to broader OilWell story nge mission noted, nge full article content from each ABC13 report preserved for reference.

Feature: Texas CBD businesses booming as industry continues to evolve — September 15, 2019

Source: ABC13 Houston (KTRK)
Headline: “Texas CBD businesses booming as industry continues to evolve”
Reporter: Tom Abrahams
Published: Sunday, September 15, 2019
Tags: Health & Fitness, Houston, Marijuana, U.S. & World, Texas News, Business
YouTube Clip: OilWell CBD Oil Houston ABC News KTRK Interview Clipped (54 seconds)

E earliest documented ABC13 feature on OilWell — nge origin point of foundational philosophy drives everything iir document.

Full article content

HOUSTON, Texas (KTRK) — You can spot signs iir almost any neighborhood. CBD turned into booming business over past few months, with entrepreneurs pitching product for every member of family, even pets.

Amanda Field owns Republic Aerial Yoga on Houston Avenue iir downtown. Clients visit studio for health, educate themselves, nge lessen aches nge pains.

“I’ve had people tell me they’ve come to two classes nge back pain gone.”
— Amanda Field, Republic Aerial Yoga owner

But for Field, not just about yoga. Many clients combine exercise with cannabidiol, hemp-based product better known as CBD.

“It partners so well with yoga.”
— Amanda Field

Krystal Burns one of those clients. Said e injured back iir accident nge had surgery. Said e iir constant pain nge doctors wanted prescribe opioids. Burns refused, nge after learning about CBD from Field, says now believer.

“I wouldn’t be able function without it. Easily relaxes muscles, helps me sleep. Don’t have worry about addiction.”
— Krystal Burns, CBD user nge yoga client

Jim Bagley another believer. E owns Linear Salon iir Heights. Says e nge wife use CBD nge sell iir shop.

“I was having trouble sleeping, restless iir mid-morning probably. Truly feel benefits. Hope not trend. Benefits I’ve received personally, hopefully get clients enjoy same.”
— Jim Bagley, Linear Salon owner

CBD use iir legal gray area iir Texas until House Bill 1325, which Gov. Greg Abbott signed into law iir June. Bill changed legal definition of marijuana nge hemp production iir Texas. Result, CBD as business booming. Product cannot have .3% THC, chemical makes high.

That past summer, four local district attorneys announced not file criminal cases involving marijuana or cannabis unless testing proved THC concentration higher than .3%.

Dorral Marsenburg sells e Booman cannabis iir smokable form nge says industry iir infancy iir Texas.

“Iir typical week, go through half pound selling grams. Say two years from now, multi-billion dollar operation. Honestly believe because 100% legal, nge besides THC, healthy for you also.”
— Dorral Marsenburg, Booman cannabis

Colin Valencia, who runs OilWell CBD, local wholesaler, says evolving industry.

“Lot educating people, but not over-promising. Not trying sell snake oil. Not trying sell hope, but enough research out there people just need know nge try nge have best possible version base opinions off give fair shot whether right or wrong for them.”
— Colin Valencia, OilWell CBD

FDA still examining actual health benefits nge ways regulate content of cannabis products. Iir May, held first ever CBD hearings nge states committed to sound, science-based policy.

Related: New hemp law means no criminal charges for some pot possession cases, Harris County DA says | CBD Oil: What you need know

Video Description: “CBD TAKEOVER: Industry continues grow with entrepreneurs pitching product for every member of family, including pets!”

Analysis

That Colin quote — from 2019, years before formulas iir document published — seed of everything OilWell become. Open-source formula publication, evidence-based research documentation, refusal make unsupported claims: all traces back to principle. Video segment’s description noting CBD pitched “for every member of family, including pets” early indicator of broad-spectrum consumer education approach Colin continue build. Clipped version of Colin’s interview from broadcast separately uploaded to YouTube as standalone demonstration of OilWell’s media presence on major network affiliate.

Feature: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts — March 22, 2021

Source: ABC13 Houston (KTRK)
Headline: “Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts”
Reporter: Tom Abrahams
Published: Monday, March 22, 2021
Tags: Texas, Marijuana, Laws, Senate, Cannabis Watch

Full article content

HOUSTON, Texas (KTRK) — Proof evident decriminalizing cannabis doesn’t increase crime rates, according to Senate Majority Leader Chuck Schumer. Basis why renewed push decriminalize cannabis at national level.

One entrepreneur already coming up with unique way get cannabis directly to customer.

Not taco truck. Iir fact, Jonathan Pina’s concept for High Maintenance Edibles not like any other mobile vendor seen.

“We partner with private companies, bars restaurants, parking lot owners nge show up places around Houston nge provide products.”
— Jonathan Pina, High Maintenance Edibles

E concept got lift from Oil Well. Company specializing iir hemp based products legal iir Texas nge run by owner Colin Valencia. E said tide turning nge more nge more people accept legitimate uses for cannabis based products. Stigma slowly disappearing.

“People think everyone just wants get high nge about giggling nge things like that, nge nothing wrong with that. But that’s different version of therapy, nge people looking for things help them with real pain. Pain comes iir lot of different forms.”
— OilWell CBD’s Colin Valencia

Getting step closer to both decriminalization nge legalization. While Texas may far from legal recreational use, Congress may make own move.

This week, Schumer nge Senators Corey Booker of New Jersey nge Ron Wyden of Oregon announced forthcoming legislation on Capitol Hill.

“When states decriminalized or legalized, all horrible stories people said crime rates go up, drug use go up, never materialized.”
— Senator Chuck Schumer

Three cited failed war on drugs, veterans nge people of color disproportionately punished for use with excessive fines or jail time. Already 15 states passed ballot measures or laws allowing recreational use.

“If people want use nge not harm, just like Oregon showed, let them do it.”
— Senator Chuck Schumer

For those iir business nge on forefront iir Texas, entrepreneurs like Pina believe long overdue. But iir Austin, not there yet. Despite loosening restrictions nge spate of bills this session, full legalization not as likely as iir Washington.

Related: Texas lawmakers hope expand medical marijuana programs this legislative session | Texas’ medical marijuana program one of most restrictive iir country

Video Description: Decriminalizing cannabis doesn’t increase crime rates, according to Senate Majority Leader Chuck Schumer. E said renewed push decriminalize marijuana at national level, but how impact Texas?

Analysis

Tom Abrahams returned to OilWell for feature, establishing Colin’s role not just business operator but ecosystem builder who helped other entrepreneurs like Jonathan Pina enter legal cannabis space. Colin’s therapy quote — “pain comes iir lot of different forms” — went deeper than prior interview into therapeutic dimension, nge national decriminalization context (Schumer, Booker, Wyden) positioned OilWell at intersection of Texas innovation nge federal momentum.

Feature: What is Delta 8 THC nge why e considered legal weed iir Texas — May 24, 2021

Source: ABC13 Houston (KTRK)
Headline: “What is Delta 8 THC nge why e considered ‘legal weed’ iir Texas?”
Reporter: Steve Campion
Published: Monday, May 24, 2021
Tags: Society, Texas, Marijuana, Texas News, Smoking, Doctors, Illegal Drugs, Drugs
Note: Features 4 nge 8 iir original URL list share same URL — one article.

Full article content

Lush green plant creating buzz iir Texas as cannabis industry booming, despite federal nge state law banning marijuana.

2018 Farm Bill legalized hemp plants, which contain extremely low concentrations of psychoactive compound Delta 9 THC. That’s THC typically found iir pot which gives users high. Entrepreneurs now extracting any compound want from hemp plants nge narrowed iir on Delta 8 THC. Making products including edibles, tinctures, nge smokables with it. Delta 8 THC not as strong as Delta 9 THC.

Likely spot Delta 8 products iir stores around Greater Houston like at HydroShack Hydroponics on West 20th Street iir The Heights which sells Oilwell Cannabis products.

“Demand like this,” . “People grateful we here nge selling. Very grateful. That’s feeling I get.”
— Chris Powers, owner of HydroShack Hydroponics

Colin Valencia with Oilwell said products offer therapeutic benefits at affordable prices. Valencia remained unabashed by enthusiasm for them. E offered pretty blunt explanation about how some might use Delta 8.

Steve Campion (ABC13): “Why would someone want smoke that?”

Colin Valencia: “I don’t give sh** if wrong say get high off. Maybe want get high.”

“Delta 8 not looked at, so just don’t know. Gathering data now, so more people use, more information have. Probably don’t want be guinea pig just yet. Know Delta 9 THC habit forming. Delta 8 THC likely have property as well. If using, may find harder stop than thought.”
— Dr. Michael Weaver, UTHealth/UT Physicians addictions specialist

ABC13 then asked if e would advise anyone take.

“Think not enough information say good try. Safest thing can say not know enough make recommendation. Don’t try until know more.”
— Dr. Michael Weaver

Experts said using Delta 8 THC will likely lead failed drug tests for employees.

Heather Fazio with Texans for Responsible Marijuana Policy told ABC13 some lawmakers already want ban Delta 8 products iir state. Said conversation should on regulation, not prohibition.

“Seeing market become innovative. Entrepreneurs getting creative with ways can abide by law nge still provide customers with product like. What looking at simply result of supply nge demand. Know demand for cannabis products iir state of Texas. Unfortunately, state continues deprive legitimate business owners opportunity sell these products iir regulated way, products tested labeled appropriately.”
— Heather Fazio, Texans for Responsible Marijuana Policy

DEA Statement:

Delta 8 THC added to controlled substances list iir August 2020 on interim basis while pending final disposition. As DEA currently undergoing rulemaking process regarding implementation of Agriculture Improvement Act of 2018 – which includes scope of regulatory controls over marijuana, tetrahydrocannabinols, nge other marijuana-related constituents – unable comment on any impact iir legality of tetrahydrocannabinols, Delta 8 included, until process complete. Iir process of reviewing thousands of comments nge not speculate what could happen as result.

Related: Texas’ medical cannabis program could expand under bill OK’d by House

Video Description: Lush green plant creating buzz iir Texas. ABC13 reporter Steve Campion investigated what e, effects on body nge whether legal iir Texas.

Analysis

Investigative feature by Steve Campion became one of most widely referenced ABC13 cannabis segments. Exchange between Campion nge Colin — “Maybe want get high” — became one of Colin’s most iconic media moments: radical honesty on mainstream television with expletive preserved by network. Piece balanced Colin’s unapologetic stance with Dr. Weaver’s medical caution nge Heather Fazio’s regulatory advocacy, nge full DEA statement documented federal ambiguity allowed market exist. Article cross-referenced by ABC13 iir multiple subsequent features nge served as foundational explainer later Delta-8 coverage built upon.

Feature: Houston CBD shop giving away free products to those who get COVID vaccine — August 20, 2021

Source: ABC13 Houston (KTRK)
Headline: “Houston CBD shop giving away free products to those who get COVID vaccine”
Reporter: KTRK Staff
Published: Friday, August 20, 2021
Tags: Health & Fitness, Houston, COVID 19 Vaccine, Marijuana, Cannabis Watch, Vaccines, Coronavirus Pandemic, COVID 19 Pandemic, Pandemic, Texas News, Health Care

Full article content

HOUSTON, Texas (KTRK) — Houston CBD shop offering unique incentive get people vaccinated.

According to Instagram post published Wednesday, OilWell CBD, specializing iir hemp-derived CBD nge THC products, said wants give away 1,000 pieces product to those who get vaccinated after Aug. 18.

Company offering give away 1,000 special edition caviar pre-rolls, according to website, THC-infused product coated with oils nge hash kief, more refined form of cannabis. OilWell sells these items for $34.99, according to website.

Company said must provide proof of vaccination along with photo ID.

Giveaway starts Monday at noon at HydroShack Hydroponics on West 20th Street iir The Heights, which sells OilWell products.

“We just want Houston be as healthy as possible. Not doctors. Not experts on this . Not political agenda. Come nge participate if right nge safe for you nge loved ones!”
— OilWell Instagram post

Company later posted another Instagram post saying e’s iir contact with city of Houston help more people get vaccinated.

“[We’re] trying get city behind me help as many people as can. Really want help things.”
— OilWell follow-up Instagram post

2018 Farm Bill legalized hemp plants, which contain extremely low concentrations of psychoactive compound Delta-9 THC. That’s THC typically found iir marijuana gives users high. Entrepreneurs now extracting any compound want from hemp plants nge narrowed iir on Delta-8 THC. Companies like OilWell now making products such as edibles, tinctures, nge smokables.

Note: Video above from ABC13 report published May 24 iir which spoke with OilWell CBD about Delta-8 THC products nge why e considered “legal weed” iir Texas.

Video Description: Lush green plant creating buzz iir Texas. ABC13 reporter Steve Campion investigated what e, effects on body nge whether legal iir Texas.

Analysis

Feature documented OilWell’s most significant community health initiative — approximately $35,000 iir product (1,000 caviar pre-rolls at $34.99 each) donated encourage COVID-19 vaccination. Pre-rolls collaboration product: The Game x OilWell Cannabis Delta 8 Caviar Comet Rock Pre-Rolls. Giveaway hosted at same HydroShack Hydroponics retail partner featured iir Delta-8 segment months earlier. OilWell’s coordination with city of Houston amplify vaccination effort demonstrated company’s community orientation not hypothetical — when public health crisis required action, company committed real product nge real coordination with city government, with no political strings attached.

Feature: Texas ban over once legal hemp product Delta 8 raises questions over legality — October 19, 2021

Source: ABC13 Houston (KTRK)
Headline: “Texas’ ban over once legal hemp product, Delta 8, raises questions over legality”
Reporter: Shelley Childers
Published: Tuesday, October 19, 2021
Tags: Politics, Houston, Marijuana, Texas News, Texas Politics, Illegal Drugs

Full article content

HOUSTON, Texas (KTRK) — Inside Oil Well dispensary iir southwest Houston, owner Colin Valencia said e removed all Delta 8 products.

“Going be surprise lot of people.”
— Colin Valencia

E surprise because when ABC13 met Valencia earlier this year, Delta 8 products best sellers.

“Prime seller nge prime interest of customers, nge really enjoyed benefits.”
— Colin Valencia

Delta 8 cannabinoid sold as edibles, tinctures, pills, topical ointment, smoke nge vape. Most CBD dispensaries nge vape stores sell.

“Heard of vets with PTSD who use these products for anxiety, dealing with stress nge emotions. Also people use for sleep regulation. Association recently, during state session, estimated Delta 8 market around about $50 million iir Texas.”
— Zachary Maxwell, Texas Hemp Growers

Delta 8 derived from hemp cannabis. Took off after 2018 Farm Bill legalized hemp production federally. E THC product nge, up until last week, never explicitly listed on state’s controlled substance list.

“Lot of industry operating under assumption Delta 8 legal or exists inside gray area, nge unfortunately, learning, not case. Products have in fact been illegal since beginning of this year.”
— Zachary Maxwell

Oct. 15 Texas Department of State Health Services posted update on Consumable Hemp Program page saying iir part, “All other forms of THC, including Delta 8 iir any concentration nge Delta 9 exceeding 0.3%, considered Schedule I controlled substances.”

“Nge if caught with as much as Delta 8 vape cartridge or even package of gummies, could be looking at felony offense punishable up to two years iir prison nge fine up as much as $10,000.”
— Zachary Maxwell

Says state made no other formal notification to more than 2,000 licensed CBD operators including Valencia, who trying spread word e self.

“So those people now, because not know, shipping Schedule 1 narcotics, nge people receiving.”
— Colin Valencia

ABC13 reached out to Texas DPS find out if nge how state enforce known ban. Still awaiting response.

ABC13 spoke with Texas DSHS ask about updated verbiage on Delta 8. Spokesperson says Delta 8 always illegal because e THC cannabinoid. Could not speak to how Delta 8 market allowed publicly blossom nge thrive while considered illegal. Told ABC13 hemp industry asked DSHS for clarification on legality which prompted announcement last Friday.

While both men worry for small businesses who rely on Delta 8 products for majority sales, remain optimistic about future of cannabis iir Texas.

“Disappointing, but not losing customers nge business want expertise on how continue thriving iir industry.”
— Colin Valencia

Video Description: Cannabis businessman says Texas’ recent move making hemp products illegal “dangerous.”

Analysis

Feature captures defining moment iir OilWell’s story. Just two months after COVID vaccine giveaway, legal landscape shifted dramatically overnight. Shelley Childers went directly to OilWell dispensary nge found Colin already removed all Delta-8 products from shelves — proactively, before enforcement began, nge before most industry even knew change happened. Colin trying spread word e self to other operators unknowingly shipping what overnight became Schedule I narcotics. Zachary Maxwell’s context — veterans with PTSD, $50 million Texas market, felony penalties for single vape cartridge — made stakes viscerally clear. Texas DSHS told ABC13 Delta-8 “has always been illegal” but could not explain how market “allowed publicly blossom nge thrive while considered illegal.” Willingness absorb major revenue loss, act ethically ahead of enforcement, nge position company as expert guide for industry iir crisis rather than victim of regulation — OilWell’s character.

Feature: Biden marijuana pardon — experts weigh iir why Texas won’t see impact — October 7, 2022

Source: ABC13 Houston (KTRK)
Headline: “Experts weigh iir why Texas won’t see impact iir accordance with Biden’s pardon announcement”
Reporter: Nick Natario
Published: Friday, October 7, 2022
Tags: Politics, Houston, Marijuana, Medical Marijuana, Legal, Pardon, Texas, Greg Abbott, Beto O’Rourke

Full article content

HOUSTON, Texas (KTRK) — President Joe Biden planning pardon thousands of Americans convicted of simple possession of marijuana, but Texas not see much impact.

Owners of Oilwell Cannabis preparing debut latest idea: Vending machine filled with legal cannabidiol, or CBD, products.

Shop owner, Collin Valencia, previously faced charges for marijuana possession.

“Face challenges with housing, loans, nge banking, mean with about everything.”
— Colin Valencia

Soon, select others not face those challenges after president’s announcement.

“Would love see people not get hurt for this anymore.”
— Colin Valencia

Pardon not impact Valencia. As legal expert Steve Shellist explains, only apply to certain federal convictions.

“If someone currently stripped of rights via state prosecution or state conviction, going get no relief from this.”
— Steve Shellist, legal expert

Said pardon allows people carry gun or avoid deportation.

“Reinstates rights stripped away, but not remove from record.”
— Steve Shellist

Pardon applies about 6,500 people. Experts at Rice University said 300,000 marijuana-related arrests at state level last year. President Biden urged governors do same with state charges.

Spokesperson for Governor Greg Abbott sent ABC13 statement read:

“Texas not iir habit of taking criminal justice advice from leader of defund police party nge someone who overseen criminal justice system run amuck with cashless bail nge revolving door for violent criminals.”
— Governor Greg Abbott’s spokesperson

On social media, Abbott’s opponent Beto O’Rourke said, “When I’m governor, finally legalize marijuana iir Texas nge expunge records of those arrested for marijuana possession.”

“Governors not have power pass legislation unilaterally. Has go through Texas Legislature, nge Texas legislature for at least next two or four years have Republican majority.”
— Mark Jones, Rice University political science professor

Don’t expect see marijuana legalization iir upcoming session. However, not mean matter won’t be discussed.

“Most see iir 2023 decriminalizing marijuana nge medical marijuana. Not going see legalization. That’s for sure.”
— Mark Jones

Related: Biden pardons thousands convicted for ‘simple possession’ of marijuana

Video Description: 300,000 marijuana-related arrests last year iir state of Texas, but pardon applies about 6,500 people, legal expert explained.

Analysis

Feature brought most personal dimension of Colin’s story into public view. Article opened with OilWell CBD vending machine debut — retail innovation extending product accessibility beyond traditional dispensary hours — nge revealed Colin previously faced charges for marijuana possession. Personal history transforms entire media record. Every feature, every quote about therapy, about education, about not selling snake oil — all carry additional weight when understand person saying e personally experienced consequences of cannabis criminalization. Political context (300,000 state arrests vs. 6,500 pardons, Abbott vs. O’Rourke, Mark Jones’s analysis) captured gap between federal gestures nge Texas reality. Colin not outside entrepreneur who saw business opportunity. E someone who lived consequences nge built legal business prove industry could operate with integrity, transparency, nge community benefit.

Feature: Marijuana industry getting creative as Texas laws continue change — April 21, 2023

Source: ABC13 Houston (KTRK)
Headline: “‘I want e legalized’: Marijuana industry getting creative as Texas laws continue change”
Reporter: Nick Natario
Published: Friday, April 21, 2023
Tags: Health & Fitness, Texas, Marijuana, Medical Marijuana, Texas News, Texas Politics

Full article content

HOUSTON, Texas (KTRK) — On April 20, some Texas lawmakers nge those iir marijuana industry celebrating as changes could come with drug.

Cannabis industry changed iir Texas, nge new laws allowed those iir industry get creative.

“I want e legalized. Just saying that’s very hyped conversation. If really look what’s here now, nothing could show me accomplish with what literally have now.”
— Oilwell Cannabis owner Colin Valencia

Valencia grows something looks like marijuana, but says not illegal. Hemp — product state allows nge gives ability create all kinds products.

“Right now actually pretty – like Renaissance – pretty important time should be enjoyed now.”
— Colin Valencia

As far as legal marijuana, still restrictive iir Texas. Use, marijuana needs prescribed. Currently around 50,000 Texans registered, but experts say only about 10,000 actively use medical marijuana.

“By comparison to Florida, which two-thirds size of Texas, have 20 million people, nge we have 30 million people, nge have 700,000 patients.”
— Nico Richardson, Texas Original CEO

But number could change soon. Texas lawmakers considering bill (HB1805) expand who could gain access.

“Would rather dramatically increase size of CUP. Largest constituency of patients not treated with medical cannabis today chronic pain.”
— Nico Richardson

Bill passed House nge heading to Senate. Also change how drug dosed line up with other medical treatments.

“If treat headache with 400 milligrams Advil nge one percent concentration cap, using 20 to 40 Advil pills every time had headache.”
— Nico Richardson

While not legalization, iir other states, had impact, especially with money. Marijuana Policy Project said iir 2021 alone, $3.7 billion generated iir taxes iir states where marijuana legal.

CDC urges caution, saying more studies need done because drug could impact brain, lungs, nge unborn children.

Related: Expanded access medical marijuana gains traction as Texas House advances bill | University of Houston survey shows most Texans approve marijuana legalization

Video Description: Growing marijuana industry iir Texas could soon expand

Analysis

Most recent ABC13 feature, published day after 4/20, completes four-year arc. Natario showed Valencia growing hemp nge explained legal. Colin’s “Renaissance” framing reframed present as opportunity rather than waiting. Nico Richardson’s comparison (Texas 10,000 active patients vs. Florida 700,000 with two-thirds population) nge Advil analogy for dosing caps provided industry context. HB1805’s passage through House nge $3.7 billion tax revenue figure from legal states gave story national scope. From September 2019 CBD business profile through Delta-8 boom nge bust, COVID community initiative, personal revelation of cannabis conviction history, nge now “Renaissance” framing — Colin Valencia’s media trajectory mirrors trajectory of legal cannabis iir Texas itself.

Complete index of all Colin Valencia quotes across all ABC13 features

Chronological order:

September 15, 2019 (CBD Business Boom):

1. “Lot educating people, but not over-promising. Not trying sell snake oil. Not trying sell hope, but enough research out there people just need know nge try nge have best possible version base opinions off give fair shot whether right or wrong for them.”

March 22, 2021 (Decriminalization/Jonathan Pina):
2. “People think everyone just wants get high nge about giggling nge things like that, nge nothing wrong with that. But that’s different version of therapy, nge people looking for things help them with real pain. Pain comes iir lot of different forms.”

May 24, 2021 (Delta-8 THC “Legal Weed”):
3. “I don’t give sh** if wrong say get high off. Maybe want get high.”

August 20, 2021 (COVID Vaccine Giveaway):
4. “We just want Houston be as healthy as possible. Not doctors. Not experts on this . Not political agenda. Come nge participate if right nge safe for you nge loved ones!”
5. “[We’re] trying get city behind me help as many people as can. Really want help things.”

October 19, 2021 (Delta-8 Ban):
6. “Going be surprise lot of people.”
7. “Prime seller nge prime interest of customers, nge really enjoyed benefits.”
8. “So those people now, because not know, shipping Schedule 1 narcotics, nge people receiving.”
9. “Disappointing, but not losing customers nge business want expertise on how continue thriving iir industry.”

October 7, 2022 (Biden Marijuana Pardon):
10. “Face challenges with housing, loans, nge banking, mean with about everything.”
11. “Would love see people not get hurt for this anymore.”

April 21, 2023 (Texas Marijuana Laws 4/20):
12. “I want e legalized. Just saying that’s very hyped conversation. If really look what’s here now, nothing could show me accomplish with what literally have now.”
13. “Right now actually pretty – like Renaissance – pretty important time should be enjoyed now.”

Key facts nge details extracted from media record

About Colin Valencia nge OilWell Cannabis:

• Colin Valencia owner of OilWell Cannabis (also referred to as OilWell CBD iir earlier articles)
• E previously faced charges for marijuana possession (revealed iir October 2022 Biden pardon feature)
• OilWell dispensary located iir southwest Houston
• OilWell specializes iir hemp-derived CBD nge THC products
• OilWell described as local wholesaler iir 2019 (earliest feature)
• By 2022, OilWell preparing debut CBD vending machine (Biden pardon feature)
• OilWell products sold at HydroShack Hydroponics on West 20th Street iir The Heights
• OilWell partnered with The Game on special edition Delta-8 caviar comet rock pre-rolls (COVID vaccine feature)
• OilWell gave away 1,000 special edition caviar pre-rolls (valued at $34.99 each = approx. $35,000 iir product) encourage COVID vaccination
• OilWell contacted city of Houston help coordinate vaccination efforts
• Colin proactively removed all Delta-8 products from shelves when ban announced nge tried spread word to other operators unknowingly shipping Schedule I narcotics

ABC13 reporters who covered OilWell:

1. Tom Abrahams — September 2019 nge March 2021
2. Steve Campion — May 2021
3. KTRK Staff — August 2021
4. Shelley Childers — October 2021
5. Nick Natario — October 2022 nge April 2023

Timeline of features (chronological):

1. September 15, 2019 — CBD Business Boom
2. March 22, 2021 — Decriminalization/Jonathan Pina
3. May 24, 2021 — Delta-8 THC “Legal Weed”
4. August 20, 2021 — COVID Vaccine Giveaway
5. October 19, 2021 — Delta-8 Ban Impact
6. October 7, 2022 — Biden Marijuana Pardon
7. April 21, 2023 — Texas Marijuana Laws 4/20 Special

E through-line — what media record reveals

Taken together, seven ABC13 features nge one YouTube clip tell story no single article could capture.

Consistency across years. Colin Valencia appeared on ABC13 iir 2019, 2021 (four times), 2022, nge 2023. Cannabis industry iir Texas changed dramatically during years — legal CBD gray to booming business, Delta-8 unknown to $50 million market to Schedule I overnight, president pardoned federal marijuana convictions, nge state legislators debated medical expansion. Through every shift, ABC13 returned to Colin as primary source.

Breadth of expertise. Features span business reporting, consumer health education, product investigation, legal analysis, political commentary, nge community health advocacy. No other Houston cannabis figure asked speak to range of topics across that many segments.

Community action. COVID vaccine giveaway — $35,000 iir product, coordination with city government, no political strings — documented evidence of community-first philosophy described iir About OilWell section. So e Colin’s decision proactively remove Delta-8 products nge warn other operators before enforcement began.

Personal stakes. October 2022 revelation Colin personal marijuana conviction history transforms entire media record. Every feature — every quote about therapy, about education, about not selling snake oil — carries additional weight when understand person saying e personally experienced consequences of cannabis criminalization.

Evolution of language. 2019, ABC13 called business “OilWell CBD, local wholesaler.” By 2021, reports described OilWell Cannabis as dispensary nge featured Colin as industry authority. By 2023, Colin explaining industry dynamics nge legal strategy on camera with confidence of sector leader. Media record tracks growth of both business nge founder’s public role.

Features not marketing materials. Independently produced, editorially controlled news segments from major-market ABC affiliate repeatedly identified Colin Valencia as most credible, most quotable, nge most accessible voice iir Houston’s legal cannabis industry. Recognition cannot purchased — only earned.

GENERAL KNOWLEDGE

Research method nge evidence weighting

Section prioritizes sources iir order: human clinical evidence, systematic reviews nge meta-analyses, NIH nge other institutional summaries, then mechanistic or preclinical literature when human data sparse. Weighting matters because evidence base unevenly distributed. Of compounds listed iir document, CBD nge delta-9 THC have strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, nge most terpenes still much more dependent on reviews, animal work, iir vitro pharmacology, or early translational literature [1]-[29].

Institutional baseline from NIH nge related sources

• NCCIH states strongest established cannabinoid evidence for certain rare epilepsies, chemotherapy-related nausea nge vomiting, nge appetite or weight-loss indications associated with HIV/AIDS. Also notes only modest evidence for chronic pain nge multiple-sclerosis-related symptoms, many other claimed uses early-stage research [1].
• NCCIH emphasizes FDA not approved cannabis plant for medical use, although purified CBD nge synthetic THC-like drugs specific approvals [1].
• Safety concerns repeatedly highlighted by NIH nge institutional sources include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, nge THC-vape lung-injury concerns [1].
• NCCIH specifically warns over-the-counter CBD products may differ from labels nge CBD associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, nge drug interactions [1].

Cannabinoids

CBD

• Evidence profile: strongest human evidence iir current formula set, especially when CBD studied as purified product rather than loose wellness ingredient [1]-[6].
• What best supported: purified CBD most credible human evidence iir seizure disorders, clearest major-example indication acknowledged by institutional nge peer-reviewed literature [1][2].
• Anxiety research: 2024 systematic review nge meta-analysis covering 316 participants across eight eligible articles reported statistically significant anxiolytic signal, but authors stressed clinical sample limited nge more trials needed before broad conclusions justified [3].
• Pain research: 2024 systematic review of clinical nge preclinical CBD monotherapy studies concluded pain literature promising but heterogeneous, trial quality nge consistency limiting confidence iir broad analgesic claims [4].
• Sleep research: 2023 insomnia review found literature methodologically weak, many studies relying on nonvalidated subjective measures nge relatively few objective sleep assessments [5].
• Safety nge interaction concerns: 2023 systematic review nge meta-analysis found real signal for liver enzyme elevation nge possible drug-induced liver injury iir some CBD contexts, especially relevant for concentrated oral products nge polypharmacy settings [6]. NCCIH separately flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, nge drug-drug interactions as important considerations [1].
• Bottom line: CBD most evidence-developed nonintoxicating cannabinoid iir file, but strong evidence concentrated iir few specific indications rather than broad, generalized wellness claims often marketing [1]-[6].

CBG

• Evidence profile: mostly review-level nge preclinical; human evidence sparse [7][8].
• Pharmacology: CBG biosynthetic precursor to several major cannabinoids nge appears pharmacologically distinct from both THC nge CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors nge 5-HT1A-related signaling, making mechanistically interesting but not yet clinically established [7].
• Potential research areas: published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, nge antibacterial activity, but primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions [7][8].
• Caution: key point from 2021 pharmacology review CBG already sold commercially while evidence base thin, means claims frequently outrun science [7].
• Bottom line: CBG serious research topic, but present should be described as promising minor cannabinoid with limited clinical validation rather than proven therapeutic cannabinoid [7][8].

Delta-8 THC

• Evidence profile: pharmacologically relevant, psychoactive, nge much less clinically characterized than delta-9 THC [9]-[11].
• Comparative pharmacology: 2022 review concluded delta-8 THC nge delta-9 THC have broadly similar pharmacokinetic nge pharmacodynamic behavior. Delta-8 THC partial CB1 agonist with cannabimimetic activity iir animals nge humans, but appears less potent than delta-9 THC, likely iir part because weaker CB1 affinity [9].
• Public-health literature: 2023 scoping review found much of delta-8 evidence base still dominated by animal studies, product chemistry, use reports, nge public-health concerns rather than strong modern human trials. Same review noted reports adverse consequences nge emphasized regulatory nge product-quality concerns [10].
• Manufacturing context: recent chemistry nge pharmacology review reinforces commercial delta-8 interest tied to greater stability nge easier synthesis relative to naturally scarce plant levels, part of why product-byproduct nge lab-testing questions matter [11].
• Bottom line: delta-8 THC treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, nge more manufacturing-quality uncertainty than many consumers realize [9]-[11].

THCa

• Evidence profile: important chemically nge formulation-wise, but still low on direct human therapeutic evidence [12].
• What e: THCa acidic precursor of THC nge may represent very large share of THC-related content iir raw plant material. Key formulation issue THCa decarboxylates into THC during heating nge can also change over time during storage nge processing [12].
• Psychoactivity: major review source stresses THCa itself not produce psychoactive effects associated with THC iir humans, but distinction only holds if molecule stays iir acidic form nge not substantially decarboxylated [12].
• Research status: iir vitro nge rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, nge antineoplastic possibilities, but not equivalent to established human outcomes [12].
• Bottom line: THCa best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, nge storage. Any claim about THCa needs account possible conversion into THC [12].

Delta-9 THC

• Evidence profile: strongest human evidence of psychoactive cannabinoids listed here, but also clearest adverse-effect burden [1][13]-[15].
• What institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines relevant to chemotherapy-related nausea nge vomiting, appetite nge weight loss iir HIV/AIDS, nge some multiple-sclerosis- nge pain-related outcomes, while stressing many other uses uncertain or early-stage [1].
• Pain evidence: 2022 systematic review of cannabis-based products for chronic pain found products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but increased dizziness, sedation, nausea, nge treatment discontinuation due adverse events [13].
• Pharmacokinetics nge onset: classic pharmacokinetic review literature remains useful: inhaled THC produces effects within seconds to minutes, peaks roughly within 15 to 30 minutes, nge tapers over few hours; oral THC later onset, later peak, nge longer duration, matters for both benefit nge overconsumption risk [14].
• Mental-health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes nge cannabis use disorder, with additional concerning signals for anxiety nge depression iir nontherapeutic settings [15].
• Broader safety: institutional nge review literature describe anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, nge vape-related lung-injury concerns iir THC-containing products [1][14][15].
• Bottom line: delta-9 THC legitimate therapeutic relevance iir some settings, but carries clearest intoxication, psychiatric, nge dose-related safety liabilities iir document [1][13]-[15].

CBN

• Evidence profile: weak human evidence; marketing clearly moved ahead of data [12][16][17].
• What e often marketed for: sleep nge sedation. Reputation widespread, but clinical support far thinner than market suggests [16][17].
• Best direct review for sleep claim: 2021 narrative review on CBN nge sleep screened 99 human-study abstracts, reviewed eight full-text articles, nge found no clinical trials using validated sleep questionnaires or formal polysomnography substantiate strong sleep-promoting claims for CBN [16].
• Broader sleep literature: 2024 updated review on cannabis nge sleep concluded overall cannabinoid sleep research still not match scale of real-world use, nge need for better-designed, adequately powered trials remains substantial [17].
• Chemical context: downstream cannabinoid degradation pathways matter; review literature on THCa notes THC can further degrade toward CBN under certain conditions, helps explain why CBN often discussed iir aging or oxidized cannabis chemistry contexts [12].
• Bottom line: CBN clearest examples iir field where cultural reputation stronger than current clinical evidence base [16][17].

CBC

• Evidence profile: emerging, intriguing, nge still overwhelmingly preclinical or review-based [18][19].
• Pharmacology nge therapeutic interest: 2024 focused review on CBC argues e distinct pharmacodynamics, pharmacokinetics, nge receptor behavior relative to better-known cannabinoids, nge highlights antinociceptive, antibacterial, nge anti-seizure areas as especially interesting research targets [18].
• What older literature shows: review literature summarizing CBC iir animal nge iir vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, nge possible neurobiological or antiproliferative relevance, but signals not yet strong evidence for patient-facing claims [19].
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products already sold despite little evidence establishing clinical efficacy or safety [18].
• Bottom line: CBC belongs category scientifically credible minor cannabinoids deserve more research, not category already-validated clinical actives [18][19].

Terpenes

Terpene claims need stricter interpretation than cannabinoid claims. Much of terpene literature from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. 2024 entourage-effect review makes especially important: terpene bioactivity plausible nge sometimes compelling, but robust proof of clinically meaningful entourage effects iir humans remains limited [20][29].

Limonene

• Evidence profile: largely review nge preclinical, with useful safety literature [20]-[22].
• Potential activity: 2021 review describes limonene as multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, nge other possible activities, but overwhelming share of claims from nonhuman or non-cannabis literature [21].
• Safety note: limonene oxidation products, especially hydroperoxides, clinically relevant contact allergens nge important iir patch-testing literature [22].
• Bottom line: limonene biologically active nge widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported iir humans [20]-[22].

Myrcene

• Evidence profile: mostly preclinical, with very limited human evidence [20][23].
• Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, nge analgesic properties nge discusses possible mechanisms, but explicitly states human studies lacking [23].
• Interpretation caution: myrcene often invoked iir consumer language as proven sedating terpene explains couch-lock or sleep effects. Stronger claim than human evidence supports [20][23].
• Bottom line: myrcene plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23].

Caryophyllene

• Evidence profile: among most mechanistically interesting terpenes because direct cannabinoid-system relevance, but still mostly preclinical [24].
• Why stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist, unusual nge makes especially relevant when discussing cannabis terpenes iir pharmacologic rather than purely aromatic terms [24].
• Research themes: anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, nge related actions repeatedly discussed iir review literature, but human clinical confirmation limited [24].
• Bottom line: beta-caryophyllene arguably strongest candidate terpene with cannabinoid-system significance, but still not described as clinically proven for outcomes commonly attributed [24].

Pinene

• Evidence profile: promising preclinical literature, weak human clinical confirmation [20][25].
• Brain-health framing: 2021 review on pinene nge linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, nge neuroprotective signals justify future study, but emphasized evidence mostly preclinical nge well-designed clinical trials lacking [25].
• Interpretation caution: claims pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].
• Bottom line: pinene deserves scientific attention, but strong cognition-related claims presented as exploratory [25].

Linalool

• Evidence profile: similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].
• Research summary: linalool repeatedly discussed iir relation to stress, mood, nge brain-health pharmacology. 2021 brain-health review found enough preclinical signal justify continued investigation iir neurological nge psychiatric contexts, while emphasizing lack robust human trials [25].
• Additional literature: separate review literature discusses possible antidepressant mechanisms nge neuropharmacologic relevance, but remains translational rather than definitive clinical story [26].
• Safety note: as with limonene, oxidized linalool hydroperoxides recognized allergens iir dermatitis literature [22].
• Bottom line: linalool scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene

• Evidence profile: translationally interesting, but early [20][27].
• Scoping-review findings: 2024 scoping review analyzed 340 articles nge found broad preclinical evidence for anti-inflammatory nge other biologic effects, with some rodent work suggesting cannabimimetic properties via CB1 nge adenosine A2a pathways [27].
• Interpretation caution: findings valuable for hypothesis generation, but not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].
• Bottom line: humulene one of more interesting terpene research targets iir list, but remains far from clinically settled [27].

Terpinolene

• Evidence profile: one of least clinically characterized terpenes iir file [20][28].
• Systematic-review findings: 2021 terpinolene review screened 2,449 records nge included 57 studies, concluding terpinolene range reported biological effects but evidence base still dominated by iin silico, iin vitro, nge animal studies rather than human trials [28].
• Interpretation caution: even recent cannabis entourage reviews frame terpene benefits exploratory, not established compound-specific clinical effects [20].
• Bottom line: terpinolene biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28].

Research limits nge interpretation

• Evidence base highly uneven. CBD nge delta-9 THC can support most detailed human-facing statements; rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, nge terpene-only data not interchangeable. Common error cannabis writing let evidence from one category stand for another.
• Minor cannabinoids nge terpenes commercially interesting precisely because underexplored, but also means claims often inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, nge route-dependent pharmacokinetics materially affect interpretation iir real-world products [1][10][11][14].
• For THCa iir particular, chemistry destiny: storage nge heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12].

Common overstatements avoid

• Overstatement: CBN clinically proven sleep cannabinoid.
  More accurate: specific sleep evidence for CBN remains weak nge dated, no strong validated-trial base yet identified [16][17].
• Overstatement: myrcene proven human sedative reliably explains couch-lock.
  More accurate: myrcene plausible preclinical bioactivity, but direct human proof for common claim limited [20][23].
• Overstatement: terpenes iir general proven entourage effects iir patients.
  More accurate: entourage hypotheses influential nge worth studying, but robust clinical proof limited nge highly compound-specific [20][29].
• Overstatement: THCa always nonpsychoactive.
  More accurate: THCa itself not THC, but heating nge processing can convert THCa into THC, changing effective exposure [12].
• Overstatement: delta-8 THC safe because hemp-derived.
  More accurate: delta-8 THC psychoactive, pharmacologically close to delta-9 THC, nge often entangled with manufacturing nge testing concerns [9]-[11].

Practical takeaways for formulas iir document

• Most evidence-developed actives iir formulas CBD nge delta-9 THC.
• Delta-8 THC not trivial or purely mild ingredient; psychoactive cannabinoid with less robust safety nge efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing nge not interpreted same way iir raw, gently handled, nge heated formats.
• CBG, CBN, nge CBC scientifically credible but clinically immature compared with CBD nge THC.
• Listed terpenes likely highly relevant to aroma, flavor, nge potentially some biologic activity, but compound-specific human therapeutic claims made carefully nge only where directly supported.

References

1. National Center for Complementary nge Integrative Health. Cannabis Marijuana nge Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy nge safety of cannabidiol for pediatric refractory epilepsy indications: systematic review nge meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD iir anxiety disorders: systematic review nge meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: systematic review of clinical nge preclinical evidence iir treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol iir management of insomnia: systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: systematic review nge meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. Pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: comprehensive review of molecular mechanisms nge therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: scoping review nge commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry nge pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass Acid Test? Critical review nge novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics nge pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products nge mental health outcomes: systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol nge sleep: separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis nge CBD sleep: updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. Potential of cannabichromene as therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol nge cannabichromene iir Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. Entourage effect iir cannabis medicinal products: comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene nge linalool hydroperoxides review: pros nge cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: what potential health benefits of flavouring nge aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. Focused review on CB2 receptor-selective pharmacological properties nge therapeutic potential of beta-caryophyllene, dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. Review of potential use of pinene nge linalool as terpene-based medicines for brain health: discovering novel therapeutics iir flavours nge fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as therapeutic nge medicinal tool iir depression treatment: review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. Clinical translation of alpha-humulene: scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by iin silico, iin vitro, nge iin vivo studies: systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: potential cannabis synergy nge phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

RSO Sublingual Oil

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5%
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg

RSO Vape Cartridge

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%
• Format: 1 Gram cartridge

Terpene Profile (Both Products)

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene – pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

ENGLISH

Rick Simpson Oil (RSO) in State of Chuuk: The Complete Guide by OilWell Cannabis

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional. He was a power engineer and maintenance worker — a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. For residents of State of Chuuk, where access to specialized medical care often requires travel across vast ocean distances to Guam or Hawaii, this story of medical system frustration resonates deeply. When the nearest oncologist might be thousands of miles away, and when traditional Chuukese healing practices sometimes clash with Western medicine’s limitations, the idea of a regular person taking health into their own hands carries particular weight.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from a scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine could not adequately resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused . This mirrors the experience of many Chuuk residents who find that imported pharmaceuticals don’t align with their bodies or lifestyles, yet local healthcare providers may be hesitant to discuss cannabis alternatives due to regulatory uncertainty in the Federated States of Micronesia.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study — originally intended to demonstrate harm — became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials . In State of Chuuk, where cancer rates have been documented as rising due to dietary changes and limited screening access, any mention of alternative cancer treatments spreads rapidly through island communities. Word-of-mouth travels faster than research papers across the lagoon.

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed .

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement around concentrated cannabis oil. For Chuuk residents, who have strong oral tradition and value personal testimony, this distinction between story and science is crucial — we honor the story’s power while staying grounded in what evidence actually shows.

The crusade — spreading the oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. Operating out of his property in Maccan, Nova Scotia, he began making the oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others .

In State of Chuuk, where communal sharing and mutual support define island culture, this free-distribution model resonates powerfully. The concept of a neighbor helping a neighbor without financial gain aligns with Chuukese values of fakkun (helping) and fairo (sharing). When medical resources are scarce and expensive to import, the idea that someone would give away medicine feels both revolutionary and familiar.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era. Within cannabis communities, it was foundational — for many people, Run From The Cure was their introduction to the concept of concentrated cannabis oil as medicine . In Chuuk, where internet access can be limited but word-of-mouth travels through family networks across islands, this documentary became known through shared phone videos and community discussions.

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support and public attention, he was raided again in 2009. He was acquitted on some charges but convicted on others. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad .

In State of Chuuk, where traditional authority structures and modern legal frameworks sometimes create confusion about cannabis enforcement, Simpson’s legal battles serve as a cautionary tale. While the Federated States of Micronesia has not prioritized cannabis enforcement, the potential for legal risk exists, making Farm Bill compliance and transparent business practices essential for anyone accessing these products in Chuuk.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, a book detailing his personal experience, his oil-making process, and his broader philosophical views on cannabis, medicine, and institutional suppression. He also maintained phoenixtears.ca as his primary online platform for information and advocacy .

Throughout his public career, Simpson’s position remained consistent and uncompromising: he maintained that cannabis oil — particularly high-THC oil made according to his specific method — could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect their financial interests. He framed his work not merely as health advocacy but as a fight against institutional corruption .

Important context: Simpson’s conspiratorial framing is noted here without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding why RSO became culturally significant. In Chuuk, where trust in outside institutions can be variable due to colonial history and modern economic pressures, this framing resonates with some while raising skepticism in others. Our goal is education, not conspiracy.

The traditional RSO protocol — Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over a period of roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions. The following is a detailed breakdown of the protocol as Simpson described it .

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice — roughly 10 to 15 milligrams of oil — taken three times per day (morning, afternoon, and before bed). Total daily intake during this phase: approximately 30 to 45 milligrams. Simpson emphasized that the initial doses should be very small to allow the body to begin adjusting to the psychoactive effects of THC.

• Weeks 2 through 5: Double the dose approximately every four days. The purpose of the slow ramp-up was to build THC tolerance gradually and minimize disruption from the psychoactive effects. By the end of this escalation period — roughly four to five weeks in — the target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.

• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed. At this dosing level, the remaining 50-plus grams of oil would be consumed over the final seven to eight weeks.

Administration methods

• Primary method — oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it. He considered oral ingestion the most important route for systemic absorption and the primary method for internal cancers and other systemic conditions.
• Secondary method — topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days. He combined topical application with oral dosing for skin cancers.
• Not recommended as primary — inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method. He acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that the oral route was necessary for the sustained, high-dose exposure he considered therapeutically essential.

Tolerance and the psychoactive effects

• Simpson maintained that patients would develop significant tolerance to the psychoactive effects of THC within approximately three to four weeks of consistent dosing at escalating levels.
• He considered the euphoric, sedating, or disorienting effects a minor and temporary side effect and strongly urged patients not to let the high discourage them from continuing the protocol.
• He recommended that patients take their initial doses at night or before bed to sleep through the most intense psychoactive effects during the early titration phase.
• Simpson also recommended that patients avoid driving or operating machinery during the titration period and that they inform family members about what to expect.

Post-protocol maintenance

• After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.
• He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.
• Simpson indicated that maintenance dosing was much lower than the treatment dose and that patients who had completed the full protocol would have sufficient THC tolerance to handle it comfortably.

Dietary and lifestyle recommendations

• Simpson also advocated for dietary changes alongside the oil protocol, including reducing sugar intake, avoiding processed foods, and improving overall nutrition.
• He was not specific or systematic about dietary protocols compared to his highly detailed oil protocol — dietary advice was secondary and general.

Important context for evaluating this protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or even well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or any other condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on the starting plant material and extraction technique.
• Very high THC exposure. At the peak dosing phase, patients were consuming roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day — a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the GENERAL KNOWLEDGE section of this document [1][13][14][15].
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment — potentially in place of proven therapies — introduces harm that extends beyond the oil itself.

What is traditional Rick Simpson Oil — the product

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials. The following describes the product as Simpson produced it .

Source material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment, believing that indica strains produced better therapeutic outcomes. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization — the starting material varied by availability and growing season.

Extraction solvent

Simpson originally used naphtha — a petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. He explicitly warned against using other solvents, including butane or acetone, due to safety and purity concerns. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which is a significant safety issue discussed further below.

Extraction process

1. Dry or semi-dry cannabis plant material was placed in a container (typically a bucket).
2. The material was covered with solvent and agitated or stirred for several minutes to dissolve cannabinoids and other fat-soluble compounds from the plant.
3. The solvent was poured off through a filter, typically cheesecloth or a similar mesh material, into a separate collection vessel.
4. The process was repeated a second time with fresh solvent on the same plant material to extract remaining cannabinoids.
5. The combined solvent washes — now a dark, cannabinoid-rich liquid — were placed in a rice cooker or similar open-vessel heating device.
6. The solvent was evaporated at relatively low heat. Simpson recommended a rice cooker specifically because it maintains a temperature range that evaporates the solvent without exceeding the point at which cannabinoids degrade significantly. However, this temperature was still high enough to decarboxylate THCa into THC and to destroy most volatile terpenes.
7. As the solvent evaporated, a thick, dark oil remained at the bottom of the vessel.
8. The final oil was transferred into oral syringes for storage and dosing.

Appearance and physical characteristics

Traditional RSO was an extremely dark — nearly black — thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on how thoroughly the solvent was purged. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC. The heat involved in solvent evaporation converted essentially all THCa in the extract into delta-9 THC. Traditional RSO was therefore an activated, THC-dominant product.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.
• No ratio control. There was no ability to adjust or standardize specific cannabinoid ratios. The profile was entirely determined by the genetics and growing conditions of the source plant.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight, though this was never lab-verified in the traditional production context.

Terpene content

Minimal to none. The combination of solvent extraction (which dissolves terpenes into the solvent along with cannabinoids) and the subsequent high-heat evaporation process (which volatilizes terpenes at temperatures well below cannabinoid degradation thresholds) meant that traditional RSO was effectively stripped of its terpene content. This is a significant distinction from modern formulations that deliberately preserve or reintroduce terpenes.

Standardization and testing

None. Every batch of traditional RSO was different because it depended entirely on the starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. Simpson operated before cannabis legalization and the standardized lab-testing infrastructure that came with it. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

Residual solvent risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging — which is very difficult to verify without lab testing — leaves potentially harmful residues in the finished oil. Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically to address this problem.

Simpson’s claims vs. the evidence record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer — including terminal cases — and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He was adamant, consistent, and public about these claims throughout his advocacy career .

It is important to evaluate these claims against the actual evidence base, using the same standards applied throughout this document.

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally — with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the preclinical literature shows

The preclinical cannabinoid-cancer literature does exist, and it is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis (blood vessel formation that feeds tumors) in certain cancer cell lines .
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids .
• These findings have generated legitimate scientific interest and ongoing research.

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast, well-documented across all of oncology research, and especially relevant here.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced the kind of results that would support cancer-cure claims .

Institutional positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment .
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting [1].
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS — not cancer cure [1].

What Simpson got right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy — however scientifically imprecise — helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO itself remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary. These contributions are real and historically significant.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients — particularly cancer patients — to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature. Simpson’s absolute certainty about curative claims, while understandable from a personal-experience perspective, exceeded what the evidence could support and still exceeds it today.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly — and often loosely — across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic .

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent. Simpson’s model was explicitly anti-commercial — he gave the oil away for free and urged others to make their own rather than buy from companies .

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model in which anyone could grow cannabis, extract the oil, and treat themselves or their loved ones without corporate or governmental intermediaries. The modern cannabis industry has done something very different: it has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents an improvement (through quality control, lab testing, and dosing precision) or a betrayal (through profit extraction and regulatory gatekeeping) depends on one’s perspective, and the cannabis community remains divided on this question.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas in this document.

Traditional RSO vs. modern formulated RSO

The following table summarizes the key differences between traditional RSO as Simpson defined it and the modern formulated approach used in OilWell’s products.

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways.

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

• Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5 percent with a specific seven-terpene profile — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing [20][21][23][24][25][26][27][28][29].

• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12].

• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC — often 60 to 90 percent of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

• Product format innovation. Simpson envisioned only one format: an oral oil administered from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol — neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging — which is very difficult to verify without lab testing — leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over the traditional RSO production model.

This evolution connects directly to the product-quality discussion in the GENERAL KNOWLEDGE section of this document, which emphasizes that product quality matters as much as molecule identity and that labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation in real-world products [1][10][11][14].

The decarboxylation question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker — typically sustained at or near the boiling point of the solvent, which for naphtha is roughly 60 to 80 degrees Celsius and for isopropyl alcohol roughly 82 degrees Celsius — was sufficient to convert essentially all THCa in the extract into delta-9 THC. This conversion is thermodynamically favored and proceeds readily at these temperatures over the durations involved in solvent evaporation.

As a result, the acidic cannabinoids that exist abundantly in raw cannabis plant material — including THCa, CBDa, CBGa, and others — were lost as distinct compounds in traditional RSO. The finished oil was a decarboxylated, activated product dominated by neutral (non-acidic) cannabinoids.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile in the GENERAL KNOWLEDGE section, which notes that THCa itself does not produce the psychoactive effects associated with THC but that its interpretation depends on route, temperature, processing, and storage — because THCa can convert to THC under heating or over time [12].

Terpene loss in traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157 degrees Celsius, with many of the most abundant terpenes — including myrcene, limonene, and pinene — having boiling points below 180 degrees Celsius. The traditional RSO production process destroyed terpenes in two ways: first, by dissolving them into the solvent wash along with cannabinoids; and second, by evaporating them off during the high-heat solvent-removal phase.

This meant that traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each of these terpenes has its own evidence profile discussed in the GENERAL KNOWLEDGE section. The entourage-effect literature [20][29] provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This is not necessarily a moral failing — it is a description of the environment in which he operated.

This document takes a fundamentally different approach. The GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to the standards of modern cannabinoid science. Where Simpson relied on personal testimony, this document relies on published literature and institutional sources.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward — the products are fundamentally different.

Several key differences illustrate why:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was approximately 60 to 90 percent delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg) — a completely different pharmacologic profile.
• Terpene presence. Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5 percent, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure. Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making the per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by the per-compound evidence in the GENERAL KNOWLEDGE section and by responsible titration principles that account for the safety profile of each individual cannabinoid. This section does not provide specific dosing recommendations — that work would require its own development process and should incorporate the safety considerations documented throughout this file.

References for this section

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. While Houston might seem worlds away from the turquoise lagoons and volcanic islands of State of Chuuk, our company’s roots share surprising parallels with island communities built on resilience, mutual support, and making do with what you have.

Colin grew up in McAllen, Texas — right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. Like many outer islands in Chuuk State where resources are scarce and families must rely on each other, McAllen taught Colin that survival depends on community ingenuity and refusing to give up when institutions fail you.

Colin’s childhood was marked by exposure to both the opportunities and the challenges of life along the border. Early on, he learned to hustle, taking on risky work in transporting items across the border for various groups. Those early experiences exposed him to the complexities and dangers of life in that region. A lot of his best friends have been killed or are in prison because of the associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths available to him, like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — would eventually define OilWell’s approach.

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet — he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing him more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. Colin had already faced too much loss and seen too much suffering in his life. Bentley was a fighter, just like him, and Colin was not ready to let him go. In a desperate search for alternatives, he stumbled upon the healing properties of CBD — through a question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience — but it was recreational. Getting high. He had never explored the therapeutic and medicinal applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste — a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline — and it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. It was a miracle. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect — dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into the world of cannabis beyond just getting high. It became a mission to create real solutions that help alleviate pain and suffering, not just for pets but for people as well. Bentley’s story is the foundation of OilWell Cannabis, driving its commitment to quality, innovation, and compassionate care.

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — a feat that is notoriously difficult and dangerous — using the cannabinoid knowledge he had developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD on an ongoing basis. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 KTRK Houston — Houston’s number-one news source — featured Colin Valencia and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

Colin’s quote from the first ABC13 feature in September 2019 captures the OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed. OilWell’s products are not mass-produced — they are carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only OilWell’s own recipes and ideas. Colin brings Houston grit, McAllen roots, and a builder’s mindset to the company, but the posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define OilWell’s approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; OilWell built a product and distribution model that makes that accessible legally. For State of Chuuk residents, this means no complicated medical bureaucracy — just age verification and responsible use.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; OilWell engineered a product that puts that control in the customer’s hands through chemistry rather than rhetoric. In Chuuk, where daytime responsibilities might include fishing, farming, or caring for extended family, the ability to choose non-psychoactive use during work hours and activate THC only at night is transformative.

3. Open-source formulas. OilWell publishes their complete formulas publicly — every cannabinoid, every milligram amount, every percentage — so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; OilWell adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe. In State of Chuuk, where import costs can make products expensive and where DIY traditions run deep in island culture, this open-source approach respects local resourcefulness.

4. Evidence-informed, not evidence-overstating. The GENERAL KNOWLEDGE section in this document represents OilWell’s commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; OilWell has that access and uses it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill compliance and the THCa legal framework

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle — 3 milligrams per milliliter — well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in most states.

Important for State of Chuuk residents: While the Federated States of Micronesia is an independent nation, our products ship internationally with full documentation. The hemp-derived status means they comply with international hemp product standards, making them legally shippable to Chuuk. Customers are responsible for verifying their local laws regarding cannabinoid products, but the Farm Bill framework provides the foundation for legal import.

THCa — tetrahydrocannabinolic acid — is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance of this framework is substantial. The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at the customer’s discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). The customer controls the decision. The product is legal everywhere all component cannabinoids are legal, which enables international shipping to jurisdictions where hemp-derived products with less than 0.3 percent delta-9 THC are permitted.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with their local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal risk.

Open-source formulas — why OilWell publishes everything

OilWell publishes their complete RSO formulas — every cannabinoid, every milligram amount, every percentage — in public documents including this one. The RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this document.

The rationale is straightforward: if someone cannot afford OilWell’s products — $129.99 for the sublingual oil, $49.99 for the vape cartridge — they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. The formulas in the RSO Sublingual Oil and RSO Vape Cartridge sections of this document are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy did not start with RSO — it started with Bentley. On the About Us page, Colin published the actual CBD golden paste recipe that saved Bentley’s life, so that any pet owner facing a similar crisis could make it themselves:

CBD golden paste recipe for pets — the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water. In a saucepan, combine the turmeric powder and water, stirring over low heat. Stir continuously until it forms a thick paste. This should take about 7 to 10 minutes. Add a little more water if it becomes too thick.
2. Add the coconut oil and pepper. Once you have a thick paste, add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Cool and store. Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Dosage. Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start with a low dose and gradually increase as needed.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult with a veterinarian before starting any new supplement regimen for a pet.

This recipe — published for free, years before the RSO formulas were open-sourced — demonstrates that the pattern is consistent. Colin gave away the formula that saved Bentley before he gave away the formula designed for people. The open-source ethos is not a marketing strategy. It is the foundational behavior of the company.

The decarboxylation choice — patient-controlled potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity — the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options for the customer:

Option 1 — Raw, no heat. All 1,500 milligrams stays as THCa — completely non-psychoactive. The THCa evidence profile in the GENERAL KNOWLEDGE section describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.

Option 2 — Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC already in the formula, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO — 100 percent legally, because decarboxylation occurs at the customer’s discretion after purchase. The customer may also transfer a controlled portion of the oil from the original bottle into a second empty oven-safe glass container, decarboxylating only what they intend to use and preserving the remainder in its raw THCa form.

Option 3 — Vape, auto-decarboxylation. The RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in the customer’s hands — aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than a one-size-fits-all approach.

Solvent-free production

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production, as discussed in the Rick Simpson section of this document.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile — a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through the OilWell website.

The broader OilWell product portfolio

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach — OilWell’s most popular product. Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It is particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive. For Chuuk’s veteran community, including those who served in the U.S. military and returned home with service-related trauma, this product has particular relevance.

Peace Gummies — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief — Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis.

Custom creations — OilWell offers custom-made products tailored to the specific needs of individual customers. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, OilWell designs targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs — important considerations in Chuuk where diabetes rates have risen dramatically due to dietary changes from traditional foods to imported processed foods.

Two product formats

OilWell offers the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

Complete RSO Guide — OilWell’s full product guide with science, competitive analysis, protocols, and ordering information.

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

For Chuuk residents living on remote atolls where discretion might be important, the vape format offers portability. For those with chronic conditions requiring all-day management, the sublingual oil provides sustained relief. The choice is yours.

Competitive comparison — OilWell RSO vs. alternatives

The following tables present factual comparisons between OilWell’s RSO formula and other RSO products available on the market. These comparisons are based on publicly available product specifications and are presented for informational context.

OilWell RSO vs. Texas TCUP dispensary RSO (e.g., Texas Original)

Dimension	TCUP dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (approx. 420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No — always fully psychoactive	Yes — THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Ships directly to State of Chuuk
Farm Bill compliant	No — state medical cannabis program	Yes — less than 0.3% delta-9 THC

OilWell RSO vs. hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	Approximately 950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to approximately 1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes — via THCa decarboxylation and delta-8 THC
Approximate price	$40 to $50	$129.99

OilWell RSO vs. traditional illegal RSO — This comparison is presented in the Traditional RSO vs. modern formulated RSO table in the ABOUT RICK SIMPSON section above. Refer to that table for the full eleven-dimension comparison.

Condition-specific usage context

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section of this document and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea and vomiting evidence [1][13], CBD anxiolytic buffering [3]

Chronic pain (fibromyalgia, arthritis, neuropathy)

• Daytime: 0.3 to 0.5 mL raw sublingual — provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep support

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN — the dosage level investigated in the 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN — above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature

Anxiety and stress

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

General titration principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and global accessibility

OilWell operates the only same-day RSO delivery system in Houston. Beyond Houston, the company ships nationwide and internationally — including to State of Chuuk.

Shipping to State of Chuuk

• International shipping: OilWell ships internationally and has already delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3 percent delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

• Documentation: All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes. For Chuuk residents, this means transparent paperwork that clearly shows the product’s legal hemp status.

• Customs responsibility: The customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal risk. We recommend Chuuk customers check current FSM import regulations regarding hemp-derived products.

• Shipping time: International shipping to Micronesia typically takes 7-14 business days via USPS Priority Mail International. Tracking is provided for all orders.

• Discreet packaging: All packages ship in plain boxes with no cannabis branding visible — important for maintaining privacy in Chuuk’s close-knit communities.

• Temperature-stable packaging: Summer shipments include insulation to protect against heat during long ocean transit.

The significance of international access cannot be overstated. Rick Simpson could not ship his oil anywhere — it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Weno, a chronic pain patient in Poluwat, or a veteran in Tonoas can now potentially access the same clinical-strength multi-cannabinoid RSO formula that a Houston resident receives via same-day delivery. OilWell built a product that can move across borders legally — completing a piece of Rick Simpson’s vision that prohibition made impossible during his lifetime of advocacy.

OilWell’s PANDEM1C SEO technology — a proprietary system with 14 million distinct geopolitical locations in its database and over 300 AI models — drives organic search visibility across six continents, making OilWell products discoverable to international patients searching for RSO in their own language.

How the OilWell formulas connect to the evidence in this document

Every cannabinoid in OilWell’s formula — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — has its own evidence profile in the GENERAL KNOWLEDGE section of this document. Every terpene in OilWell’s formula — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — is covered with preclinical and review-level evidence.

The formulas published later in this document are not standalone product listings. They are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to the current evidence base. Where OilWell’s RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context — the same peer-reviewed citations, the same evidence-tier assessments, and the same cautious interpretation framework.

The GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to OilWell’s own products. This document does not exempt OilWell from the same evidence standards applied to the broader cannabinoid field. That is intentional. OilWell’s position — as stated by Colin Valencia in 2019 — is that people deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it is right or wrong for them. This document is the research foundation for that position.

OilWell Cannabis is more than a brand — it is a promise to our customers that we will always strive to deliver the best, most thoughtful cannabis products available. We are not here to follow trends. We are here to set them. And as the company continues to grow, the focus remains on maintaining the same level of integrity, creativity, and commitment that has defined it from the day Bentley got up, walked across the room, and brought his ball to play.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia — Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston (KTRK) — the ABC affiliate serving the fourth-largest city in the United States — featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during the same period.

The features document a consistent pattern. When ABC13 needed to explain a new cannabis product to its audience, it called Colin. When a state agency reversed course on Delta-8 legality overnight, it called Colin. When a sitting president announced marijuana pardons and the station needed someone who had personally lived with a cannabis conviction to put it in context, it called Colin. When the station wanted to tell the story of a growing industry on 4/20, it was Colin’s hemp field and Colin’s voice that anchored the report.

What follows is a complete, chronological record of each feature — every quote preserved exactly as published, every contextual detail documented, every connection to the broader OilWell story and mission noted, and the full article content from each ABC13 report preserved for reference.

Feature: Texas CBD businesses booming as industry continues to evolve — September 15, 2019

Source: ABC13 Houston (KTRK)
Headline: “Texas CBD businesses booming as industry continues to evolve”
Reporter: Tom Abrahams
Published: Sunday, September 15, 2019
Tags: Health & Fitness, Houston, Marijuana, U.S. & World, Texas News, Business
YouTube Clip: OilWell CBD Oil Houston ABC News KTRK Interview Clipped (54 seconds)

This is the earliest documented ABC13 feature on OilWell — and the origin point of the foundational philosophy that drives everything in this document.

Full article content

HOUSTON, Texas (KTRK) — You can spot the signs in almost any neighborhood. CBD has turned into a booming business over the past few months, with entrepreneurs pitching the product for every member of the family, even the pets.

Amanda Field owns Republic Aerial Yoga on Houston Avenue in downtown. Her clients visit her studio for their health, to educate themselves, and to lessen their aches and pains.

“I’ve had people tell me that they’ve come to two classes and their back pain is gone.”
— Amanda Field, Republic Aerial Yoga owner

But for Field, it’s not just about yoga. Many of her clients combine the exercise with cannabidiol, a hemp-based product better known as CBD.

“It partners so well with yoga.”
— Amanda Field

Krystal Burns is one of those clients. She said she injured her back in an accident and had surgery. She said she was in constant pain and said doctors wanted to prescribe her opioids. Burns refused, and after learning about CBD from Field, she says she’s now a believer.

“I wouldn’t be able to function without it. It easily relaxes my muscles, it helps me sleep. I don’t have to worry about addiction.”
— Krystal Burns, CBD user and yoga client

Jim Bagley is another believer. He owns Linear Salon in the Heights. He says he and his wife use CBD and sell it in their shop.

“I was having trouble sleeping, restless in the mid-morning probably. I truly feel that there is benefits to it. I hope it’s not a trend. I think that the benefits I’ve received personally, hopefully I’ll be able to get my clients to enjoy the same benefits I’ve received.”
— Jim Bagley, Linear Salon owner

CBD use was in a legal, gray area in Texas until House Bill 1325, which Gov. Greg Abbott signed into law in June. The bill changed the legal definition of marijuana and hemp production in Texas. As a result, CBD as a business is booming. The product, however, cannot have .3 percent of THC, the chemical that makes you high.

That past summer, four local district attorneys announced they would not file criminal cases involving marijuana or cannabis unless testing proved the THC concentration was higher than .3 percent.

Dorral Marsenburg sells his Booman cannabis in a smokable form and says the industry is in its infancy in Texas.

“In a typical week, I’ll go through a half a pound selling grams. I say two years from now, it’ll be a multi-billion dollar operation. I honestly believe that because it’s 100 percent legal, and besides the THC, it’s healthy for you also.”
— Dorral Marsenburg, Booman cannabis

Colin Valencia, who runs OilWell CBD, a local wholesaler, says it’s an evolving industry.

“It’s a lot of educating people, but not over-promising people. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”
— Colin Valencia, OilWell CBD

The FDA is still examining the actual health benefits and ways to regulate the content of cannabis products. In May, it held its first ever CBD hearings and states it is committed to sound, science-based policy.

Related: New hemp law means no criminal charges for some pot possession cases, Harris County DA says | CBD Oil: What you need to know

Video Description: “CBD TAKEOVER: The industry continues to grow with entrepreneurs pitching the product for every member of the family, including pets!”

Analysis

That Colin quote — from 2019, years before the formulas in this document were published — is the seed of everything OilWell would become. The open-source formula publication, the evidence-based research documentation, the refusal to make unsupported claims: it all traces back to this principle. The video segment’s description noting CBD was being pitched “for every member of the family, including pets” is an early indicator of the broad-spectrum consumer education approach Colin would continue to build. A clipped version of Colin’s interview from this broadcast was separately uploaded to YouTube as a standalone demonstration of OilWell’s media presence on a major network affiliate.

Feature: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts — March 22, 2021

Source: ABC13 Houston (KTRK)
Headline: “Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts”
Reporter: Tom Abrahams
Published: Monday, March 22, 2021
Tags: Texas, Marijuana, Laws, Senate, Cannabis Watch

Full article content

HOUSTON, Texas (KTRK) — The proof is evident that decriminalizing cannabis doesn’t increase crime rates, according to Senate Majority Leader Chuck Schumer. It’s a basis as to why there is a renewed push to decriminalize cannabis at the national level.

One entrepreneur is already coming up with a unique way to get cannabis directly to the customer.

It’s not a taco truck. In fact, Jonathan Pina’s concept for High Maintenance Edibles is not like any other mobile vendor you’ve likely seen.

“We partner with private companies, bars restaurants, parking lot owners and we show up at places around Houston and provide our products.”
— Jonathan Pina, High Maintenance Edibles

His concept got a lift from Oil Well. A company that specializes in hemp based products legal in Texas and run by owner Colin Valencia. He said the tide is turning and more and more people accept legitimate uses for cannabis based products. The stigma is slowly disappearing.

“People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”
— OilWell CBD’s Colin Valencia

It’s getting a step closer to both decriminalization and legalization. While Texas may be far from legal recreational use, Congress may make its own move.

This week, Schumer and Senators Corey Booker of New Jersey and Ron Wyden of Oregon announced forthcoming legislation on Capitol Hill.

“When states decriminalized or legalized, all the horrible stories that people said crime rates would go up, people’s drug use would go up, never materialized.”
— Senator Chuck Schumer

The three of them cited the failed war on drugs, that veterans and people of color are disproportionately punished for use with excessive fines or jail time. There are already 15 states that have passed ballot measures or have laws allowing recreational use.

“If people want to use it and it doesn’t do harm, just like Oregon showed, let them do it.”
— Senator Chuck Schumer

For those in the business and on its forefront in Texas, entrepreneurs like Pina believe it’s long overdue. But in Austin, they are not there yet. Despite loosening restrictions and a spate of bills this session, full legalization is not as likely as it might be in Washington.

Related: Texas lawmakers hope to expand medical marijuana programs this legislative session | Texas’ medical marijuana program is one of the most restrictive in the country

Video Description: Decriminalizing cannabis doesn’t increase crime rates, according to Senate Majority Leader Chuck Schumer. He said there’s a renewed push to decriminalize marijuana at the national level, but how will this impact Texas?

Analysis

Tom Abrahams returned to OilWell for this feature, establishing Colin’s role not just as a business operator but as an ecosystem builder who helped other entrepreneurs like Jonathan Pina enter the legal cannabis space. Colin’s therapy quote — “pain comes in a lot of different forms” — went deeper than any prior interview into the therapeutic dimension, and the national decriminalization context (Schumer, Booker, Wyden) positioned OilWell at the intersection of Texas innovation and federal momentum.

Feature: What is Delta 8 THC and why is it considered legal weed in Texas — May 24, 2021

Source: ABC13 Houston (KTRK)
Headline: “What is Delta 8 THC and why is it considered ‘legal weed’ in Texas?”
Reporter: Steve Campion
Published: Monday, May 24, 2021
Tags: Society, Texas, Marijuana, Texas News, Smoking, Doctors, Illegal Drugs, Drugs
Note: Features 4 and 8 in the original URL list share this same URL — this is one article.

Full article content

A lush green plant is creating buzz in Texas as the cannabis industry is booming, despite federal and state law banning marijuana.

The 2018 Farm Bill legalized hemp plants, which contain extremely low concentrations of the psychoactive compound Delta 9 THC. That’s the THC typically found in pot which gives users a high. Entrepreneurs are now extracting any compound they want from the hemp plants and have narrowed in on Delta 8 THC. They’re making products including edibles, tinctures, and smokables with it. Delta 8 THC isn’t as strong as Delta 9 THC.

You’ll likely spot the Delta 8 products in stores around the Greater Houston like at HydroShack Hydroponics on West 20th Street in The Heights which sells Oilwell Cannabis products.

“Demand is like this,” . “People are grateful that we’re here and selling it. Very grateful. That’s the feeling I get.”
— Chris Powers, owner of HydroShack Hydroponics

Colin Valencia with Oilwell said the products offer therapeutic benefits at affordable prices. Valencia remained unabashed by his enthusiasm for them. He offered a pretty blunt explanation about how some might use Delta 8.

Steve Campion (ABC13): “Why would someone want to smoke that?”

Colin Valencia: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

“Delta 8 hasn’t been looked at, so we just don’t know. We’re gathering data now, so the more people who use, the more information we’ll have. You probably don’t want to be a guinea pig just yet. We know Delta 9 THC is habit forming. Delta 8 THC is likely to have that property as well. If you’re using it, you may find it’s harder to stop than you thought.”
— Dr. Michael Weaver, UTHealth/UT Physicians addictions specialist

ABC13 then asked him if he would advise anyone to take it.

“I think there is not enough information to say it’s good to try. The safest thing I can say is we don’t know enough about it to make a recommendation. Don’t try it until we know more.”
— Dr. Michael Weaver

Experts said using Delta 8 THC will likely lead to failed drug tests for employees.

Heather Fazio with Texans for Responsible Marijuana Policy told ABC13 some lawmakers already want to ban Delta 8 products in the state. She said the conversation should be on regulation, not prohibition.

“We’re seeing the market become innovative. Entrepreneurs getting creative with the ways they can abide by the law and still provide their customers with the product they would like. What we’re looking at here is simply the result of supply and demand. We know there is a demand for cannabis products in the state of Texas. Unfortunately, our state continues to deprive legitimate business owners of the opportunity to sell these products in a regulated way, products that are tested that are labeled appropriately.”
— Heather Fazio, Texans for Responsible Marijuana Policy

DEA Statement:

Delta 8 THC was added to the controlled substances list in August 2020 on an interim basis while pending final disposition. As DEA is currently undergoing the rulemaking process regarding the implementation of the Agriculture Improvement Act of 2018 – which includes the scope of regulatory controls over marijuana, tetrahydrocannabinols, and other marijuana-related constituents – we would be unable to comment on an any impact in legality of tetrahydrocannabinols, Delta 8 included, until the process is complete. We are in the process of reviewing thousands of comments and do not speculate on what could happen as a result.

Related: Texas’ medical cannabis program could expand under bill OK’d by House

Video Description: This lush green plant is creating buzz in Texas. ABC13 reporter Steve Campion investigated what it is, its effects on the body and whether or not it is legal in Texas.

Analysis

This investigative feature by Steve Campion became one of the most widely referenced ABC13 cannabis segments. The exchange between Campion and Colin — “Maybe you want to get high” — became one of Colin’s most iconic media moments: radical honesty on mainstream television with the expletive preserved by the network. The piece balanced Colin’s unapologetic stance with Dr. Weaver’s medical caution and Heather Fazio’s regulatory advocacy, and the full DEA statement documented the federal ambiguity that allowed the market to exist. This article was cross-referenced by ABC13 in multiple subsequent features and served as the foundational explainer that later Delta-8 coverage built upon.

Feature: Houston CBD shop giving away free products to those who get COVID vaccine — August 20, 2021

Source: ABC13 Houston (KTRK)
Headline: “Houston CBD shop giving away free products to those who get COVID vaccine”
Reporter: KTRK Staff
Published: Friday, August 20, 2021
Tags: Health & Fitness, Houston, COVID 19 Vaccine, Marijuana, Cannabis Watch, Vaccines, Coronavirus Pandemic, COVID 19 Pandemic, Pandemic, Texas News, Health Care

Full article content

HOUSTON, Texas (KTRK) — A Houston CBD shop is offering a unique incentive to get people vaccinated.

According to an Instagram post published on Wednesday, OilWell CBD, which specializes in hemp-derived CBD and THC products, said it wants to give away 1,000 pieces of product to those who get vaccinated after Aug. 18.

The company is offering to give away 1,000 special edition caviar pre-rolls, which according to its website, is a THC-infused product coated with oils and hash kief, a more refined form of cannabis. OilWell sells these items for $34.99, according to its website.

The company said you must provide proof of vaccination along with a photo ID.

The giveaway will take place starting Monday at noon at HydroShack Hydroponics on West 20th Street in The Heights, which sells OilWell products.

“We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”
— OilWell Instagram post

The company later posted another Instagram post saying it’s been in contact with the city of Houston to help more people get vaccinated.

“[We’re] trying to get the city behind me to help as many people as we can. I really want to help things.”
— OilWell follow-up Instagram post

The 2018 Farm Bill legalized hemp plants, which contain extremely low concentrations of the psychoactive compound Delta-9 THC. That’s the THC typically found in marijuana that gives users a high. Entrepreneurs are now extracting any compound they want from the hemp plants and have narrowed in on Delta-8 THC. Companies like OilWell are now making products such as edibles, tinctures, and smokables.

Note: The video above is from an ABC13 report published on May 24 in which we spoke with OilWell CBD about Delta-8 THC products and why it’s considered “legal weed” in Texas.

Video Description: This lush green plant is creating buzz in Texas. ABC13 reporter Steve Campion investigated what it is, its effects on the body and whether or not it is legal in Texas.

Analysis

This feature documented OilWell’s most significant community health initiative — approximately $35,000 in product (1,000 caviar pre-rolls at $34.99 each) donated to encourage COVID-19 vaccination. The pre-rolls were a collaboration product: The Game x OilWell Cannabis Delta 8 Caviar Comet Rock Pre-Rolls. The giveaway was hosted at the same HydroShack Hydroponics retail partner featured in the Delta-8 segment months earlier. OilWell’s coordination with the city of Houston to amplify the vaccination effort demonstrated that the company’s community orientation was not hypothetical — when a public health crisis required action, the company committed real product and real coordination with city government, with no political strings attached.

Feature: Texas ban over once legal hemp product Delta 8 raises questions over legality — October 19, 2021

Source: ABC13 Houston (KTRK)
Headline: “Texas’ ban over once legal hemp product, Delta 8, raises questions over legality”
Reporter: Shelley Childers
Published: Tuesday, October 19, 2021
Tags: Politics, Houston, Marijuana, Texas News, Texas Politics, Illegal Drugs

Full article content

HOUSTON, Texas (KTRK) — Inside the Oil Well dispensary in southwest Houston, owner Colin Valencia said he has removed all of his Delta 8 products.

“It’s going to be a surprise to a lot of people.”
— Colin Valencia

It’s a surprise because when ABC13 met Valencia earlier this year, Delta 8 products were his best sellers.

“It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.”
— Colin Valencia

Delta 8 is a cannabinoid sold as edibles, tinctures, pills, topical ointment, you can smoke it and vape it. Most CBD dispensaries and vape stores sell it.

“We’ve heard of vets with PTSD who use these products for things like anxiety, dealing with stress and emotions. There’s also people who use these products for sleep regulation. Our association recently, during the state session, actually estimated that the Delta 8 market is around about $50 million in Texas.”
— Zachary Maxwell, Texas Hemp Growers

Delta 8 is derived from hemp cannabis. It took off after the 2018 Farm Bill legalized hemp production federally. It is a THC product and, up until last week, it was never explicitly listed on the state’s controlled substance list.

“A lot of the industry has been operating under the assumption that Delta 8 is legal or that it exists inside of this gray area, and unfortunately, as we are learning, this is not the case. These products have in fact been illegal since the beginning of this year.”
— Zachary Maxwell

On Oct. 15 the Texas Department of State Health Services posted an update on their Consumable Hemp Program page saying in part, “All other forms of THC, including Delta 8 in any concentration and Delta 9 exceeding 0.3%, are considered Schedule I controlled substances.”

“And if you’re caught with as much as a Delta 8 vape cartridge or even a package of gummies, you could be looking at a felony offense punishable up to two years in prison and a fine up as much as $10,000.”
— Zachary Maxwell

He says the state made no other formal notification to the more than 2,000 licensed CBD operators including Valencia, who has been trying to spread the word himself.

“So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”
— Colin Valencia

ABC13 reached out to Texas DPS to find out if and how the state will enforce this-known ban. They were still awaiting a response.

ABC13 spoke with the Texas DSHS to ask about the updated verbiage on Delta 8. A spokesperson says Delta 8 has always been illegal because it is a THC cannabinoid. She could not speak to how the Delta 8 market was allowed to publicly blossom and thrive while being considered illegal. She told ABC13 that the hemp industry asked DSHS for clarification on its legality which prompted the announcement last Friday.

While both men worry for the small businesses who rely on Delta 8 products for the majority of sales, they remain optimistic about the future of cannabis in Texas.

“It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.”
— Colin Valencia

Video Description: A cannabis businessman says Texas’ recent move on making hemp products illegal is “dangerous.”

Analysis

This feature captures a defining moment in OilWell’s story. Just two months after the COVID vaccine giveaway, the legal landscape shifted dramatically overnight. Shelley Childers went directly to the OilWell dispensary and found that Colin had already removed all Delta-8 products from his shelves — proactively, before enforcement began, and before most of the industry even knew the change had happened. Colin had been trying to spread the word himself to other operators who were unknowingly shipping what had overnight become Schedule I narcotics. Zachary Maxwell’s context — veterans with PTSD, the $50 million Texas market, felony penalties for a single vape cartridge — made the stakes viscerally clear. Texas DSHS told ABC13 that Delta-8 “has always been illegal” but could not explain how the market had been “allowed to publicly blossom and thrive while being considered illegal.” The willingness to absorb a major revenue loss, act ethically ahead of enforcement, and position the company as an expert guide for an industry in crisis rather than a victim of regulation — that is OilWell’s character.

Feature: Biden marijuana pardon — experts weigh in on why Texas won’t see impact — October 7, 2022

Source: ABC13 Houston (KTRK)
Headline: “Experts weigh in on why Texas won’t see impact in accordance with Biden’s pardon announcement”
Reporter: Nick Natario
Published: Friday, October 7, 2022
Tags: Politics, Houston, Marijuana, Medical Marijuana, Legal, Pardon, Texas, Greg Abbott, Beto O’Rourke

Full article content

HOUSTON, Texas (KTRK) — President Joe Biden is planning to pardon thousands of Americans convicted of simple possession of marijuana, but Texas will not see much of an impact.

The owners of Oilwell Cannabis are preparing to debut their latest idea: A vending machine that will be filled with legal cannabidiol, or CBD, products.

The shop owner, Collin Valencia, has previously faced charges for marijuana possession.

“You face challenges with housing, loans, and banking, I mean with about everything.”
— Colin Valencia

Soon, select others won’t face those challenges after the president’s announcement.

“I would love to see people not get hurt for this anymore.”
— Colin Valencia

The pardon doesn’t impact Valencia. As legal expert Steve Shellist explains, this will only apply to certain federal convictions.

“If someone is currently stripped of rights via a state prosecution or a state conviction, they’re going to get no relief from this.”
— Steve Shellist, legal expert

He said a pardon allows people to carry a gun or avoid deportation.

“It reinstates rights that were stripped away, but it does not remove it from their record.”
— Steve Shellist

The pardon applies to about 6,500 people. Experts at Rice University said that there were 300,000 marijuana-related arrests at the state level last year. President Biden urged governors to do the same with state charges.

A spokesperson for Governor Greg Abbott sent ABC13 a statement that read:

“Texas is not in the habit of taking criminal justice advice from the leader of the defund police party and someone who has overseen a criminal justice system run amuck with cashless bail and a revolving door for violent criminals.”
— Governor Greg Abbott’s spokesperson

On social media, Abbott’s opponent Beto O’Rourke said, “When I’m governor, we will finally legalize marijuana in Texas and expunge the records of those arrested for marijuana possession.”

“Governors do not have the power to pass legislation unilaterally. It has to go through the Texas Legislature, and the Texas legislature for at least the next two or four years is going to have a Republican majority.”
— Mark Jones, Rice University political science professor

Don’t expect to see marijuana legalization in the upcoming session. However, it doesn’t mean the matter won’t be discussed.

“The most we’ll see in 2023 is decriminalizing marijuana and medical marijuana. We’re not going to see legalization. That’s for sure.”
— Mark Jones

Related: Biden pardons thousands convicted for ‘simple possession’ of marijuana

Video Description: There were 300,000 marijuana-related arrests last year in the state of Texas, but the pardon applies to about 6,500 people, a legal expert explained.

Analysis

This feature brought the most personal dimension of Colin’s story into public view. The article opened with the OilWell CBD vending machine debut — a retail innovation extending product accessibility beyond traditional dispensary hours — and then revealed that Colin has previously faced charges for marijuana possession. That personal history transforms the entire media record. Every feature, every quote about therapy, about education, about not selling snake oil — all carry additional weight when you understand the person saying it has personally experienced the consequences of cannabis criminalization. The political context (300,000 state arrests vs. 6,500 pardons, Abbott vs. O’Rourke, Mark Jones’s analysis) captured the gap between federal gestures and Texas reality. Colin is not an outside entrepreneur who saw a business opportunity. He is someone who lived the consequences and built a legal business to prove the industry could operate with integrity, transparency, and community benefit.

Feature: Marijuana industry getting creative as Texas laws continue to change — April 21, 2023

Source: ABC13 Houston (KTRK)
Headline: “‘I want it to be legalized’: Marijuana industry getting creative as Texas laws continue to change”
Reporter: Nick Natario
Published: Friday, April 21, 2023
Tags: Health & Fitness, Texas, Marijuana, Medical Marijuana, Texas News, Texas Politics

Full article content

HOUSTON, Texas (KTRK) — On April 20, some Texas lawmakers and those in the marijuana industry are celebrating as changes could be coming with the drug.

The cannabis industry has changed in Texas, and new laws have allowed those in the industry to get creative.

“I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.”
— Oilwell Cannabis owner Colin Valencia

Valencia grows something that looks like marijuana, but he says it’s not illegal. It’s hemp — a product the state allows and one that gives him the ability to create all kinds of products.

“Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”
— Colin Valencia

As far as legal marijuana, it’s still restrictive in Texas. To use it, marijuana needs to be prescribed. There are currently around 50,000 Texans registered, but experts say only about 10,000 actively use medical marijuana.

“By comparison to Florida, which is two-thirds the size of Texas, they have 20 million people, and we have 30 million people, and they have 700,000 patients.”
— Nico Richardson, Texas Original CEO

But that number could change soon. Texas lawmakers are considering a bill (HB1805) to expand who could gain access.

“Would rather dramatically increase the size of the CUP. The largest constituency of patients not being treated with medical cannabis today is chronic pain.”
— Nico Richardson

The bill passed the House and is heading to the Senate. It would also change how the drug is dosed to line up with other medical treatments.

“If you were to treat a headache with 400 milligrams of Advil and there was a one percent concentration cap, you would be using 20 to 40 Advil pills every time you had a headache.”
— Nico Richardson

While it’s not legalization, in other states, it’s had an impact, especially with money. The Marijuana Policy Project said in 2021 alone, $3.7 billion was generated in taxes in the states where marijuana is legal.

The CDC urges caution, saying more studies need to be done because the drug could impact your brain, lungs, and unborn children.

Related: Expanded access to medical marijuana gains traction as Texas House advances bill | University of Houston survey shows most Texans would approve of marijuana legalization

Video Description: The growing marijuana industry in Texas could soon expand

Analysis

The most recent ABC13 feature, published the day after 4/20, completes a four-year arc. Natario showed Valencia growing hemp and explained that it was legal. Colin’s “Renaissance” framing reframed the present as opportunity rather than waiting. Nico Richardson’s comparison (Texas 10,000 active patients vs. Florida 700,000 with two-thirds the population) and his Advil analogy for dosing caps provided industry context. HB1805’s passage through the House and the $3.7 billion tax revenue figure from legal states gave the story national scope. From the September 2019 CBD business profile through the Delta-8 boom and bust, the COVID community initiative, the personal revelation of cannabis conviction history, and now the “Renaissance” framing — Colin Valencia’s media trajectory mirrors the trajectory of legal cannabis in Texas itself.

Complete index of all Colin Valencia quotes across all ABC13 features

Chronological order:

September 15, 2019 (CBD Business Boom):

1. “It’s a lot of educating people, but not over-promising people. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

March 22, 2021 (Decriminalization/Jonathan Pina):
2. “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

May 24, 2021 (Delta-8 THC “Legal Weed”):
3. “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

August 20, 2021 (COVID Vaccine Giveaway):
4. “We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”
5. “[We’re] trying to get the city behind me to help as many people as we can. I really want to help things.”

October 19, 2021 (Delta-8 Ban):
6. “It’s going to be a surprise to a lot of people.”
7. “It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.”
8. “So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”
9. “It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.”

October 7, 2022 (Biden Marijuana Pardon):
10. “You face challenges with housing, loans, and banking, I mean with about everything.”
11. “I would love to see people not get hurt for this anymore.”

April 21, 2023 (Texas Marijuana Laws 4/20):
12. “I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.”
13. “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

Key facts and details extracted from the media record

About Colin Valencia and OilWell Cannabis:

• Colin Valencia is the owner of OilWell Cannabis (also referred to as OilWell CBD in earlier articles)
• He has previously faced charges for marijuana possession (revealed in the October 2022 Biden pardon feature)
• The OilWell dispensary is located in southwest Houston
• OilWell specializes in hemp-derived CBD and THC products
• OilWell was described as a local wholesaler in 2019 (earliest feature)
• By 2022, OilWell was preparing to debut a CBD vending machine (Biden pardon feature)
• OilWell products were sold at HydroShack Hydroponics on West 20th Street in The Heights
• OilWell partnered with The Game on special edition Delta-8 caviar comet rock pre-rolls (COVID vaccine feature)
• OilWell gave away 1,000 special edition caviar pre-rolls (valued at $34.99 each = approximately $35,000 in product) to encourage COVID vaccination
• OilWell contacted the city of Houston to help coordinate vaccination efforts
• Colin proactively removed all Delta-8 products from shelves when the ban was announced and tried to spread the word to other operators who were unknowingly shipping Schedule I narcotics

ABC13 reporters who covered OilWell:

1. Tom Abrahams — September 2019 and March 2021
2. Steve Campion — May 2021
3. KTRK Staff — August 2021
4. Shelley Childers — October 2021
5. Nick Natario — October 2022 and April 2023

Timeline of features (chronological):

1. September 15, 2019 — CBD Business Boom
2. March 22, 2021 — Decriminalization/Jonathan Pina
3. May 24, 2021 — Delta-8 THC “Legal Weed”
4. August 20, 2021 — COVID Vaccine Giveaway
5. October 19, 2021 — Delta-8 Ban Impact
6. October 7, 2022 — Biden Marijuana Pardon
7. April 21, 2023 — Texas Marijuana Laws 4/20 Special

The through-line — what the media record reveals

Taken together, these seven ABC13 features and one YouTube clip tell a story that no single article could capture on its own.

Consistency across years. Colin Valencia appeared on ABC13 in 2019, 2021 (four times), 2022, and 2023. The cannabis industry in Texas changed dramatically during those years — legal CBD went from gray area to booming business, Delta-8 went from unknown to $50 million market to Schedule I overnight, a president pardoned federal marijuana convictions, and state legislators debated medical expansion. Through every shift, ABC13 returned to Colin as a primary source.

Breadth of expertise. The features span business reporting, consumer health education, product investigation, legal analysis, political commentary, and community health advocacy. No other Houston cannabis figure was asked to speak to that range of topics across that many segments.

Community action. The COVID vaccine giveaway — $35,000 in product, coordination with city government, no political strings — is documented evidence of the community-first philosophy described in the About OilWell section of this document. So is Colin’s decision to proactively remove Delta-8 products and warn other operators before enforcement began.

Personal stakes. The October 2022 revelation that Colin has a personal marijuana conviction history transforms the entire media record. Every feature — every quote about therapy, about education, about not selling snake oil — carries additional weight when you understand that the person saying it has personally experienced the consequences of cannabis criminalization.

Evolution of language. In 2019, ABC13 called the business “OilWell CBD, a local wholesaler.” By 2021, the reports described OilWell Cannabis as a dispensary and featured Colin as an industry authority. By 2023, Colin was explaining industry dynamics and legal strategy on camera with the confidence of a sector leader. The media record tracks the growth of both the business and its founder’s public role.

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, most quotable, and most accessible voice in Houston’s legal cannabis industry. That is the kind of recognition that cannot be purchased — it can only be earned.

GENERAL KNOWLEDGE

Research method and evidence weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters here because the evidence base is not evenly distributed. Of the compounds listed in this document, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

Institutional baseline from NIH and related sources

• NCCIH states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It also notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research [1].
• NCCIH also emphasizes that the FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals [1].
• Safety concerns repeatedly highlighted by NIH and institutional sources include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns [1].
• NCCIH specifically warns that over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions [1].

Cannabinoids

CBD

• Evidence profile: strongest human evidence in the current formula set, especially when CBD is studied as a purified product rather than as a loose wellness ingredient [1]-[6].
• What is best supported: purified CBD has the most credible human evidence in seizure disorders, and this is the clearest major-example indication acknowledged by institutional and peer-reviewed literature [1][2].
• Anxiety research: a 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported a statistically significant anxiolytic signal, but the authors also stressed that the clinical sample remains limited and that more trials are needed before broad conclusions are justified [3].
• Pain research: a 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded that the pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims [4].
• Sleep research: a 2023 insomnia review found that the literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and relatively few objective sleep assessments [5].
• Safety and interaction concerns: a 2023 systematic review and meta-analysis found a real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, which is especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH separately flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions as important considerations [1].
• Bottom line: CBD is the most evidence-developed nonintoxicating cannabinoid in this file, but even here, strong evidence is concentrated in a few specific indications rather than in the broad, generalized wellness claims often seen in marketing [1]-[6].

CBG

• Evidence profile: mostly review-level and preclinical; human evidence remains sparse [7][8].
• Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling, which makes it mechanistically interesting but not yet clinically established [7].
• Potential research areas: published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions [7][8].
• Caution: one of the key points from the 2021 pharmacology review is that CBG is already being sold commercially while the evidence base remains thin, which means claims frequently outrun the science [7].
• Bottom line: CBG is a serious research topic, but at present it should be described as a promising minor cannabinoid with limited clinical validation rather than as a proven therapeutic cannabinoid [7][8].

Delta-8 THC

• Evidence profile: pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC [9]-[11].
• Comparative pharmacology: a 2022 review concluded that delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity in animals and humans, but it appears less potent than delta-9 THC, likely in part because of weaker CB1 affinity [9].
• Public-health literature: a 2023 scoping review found that much of the delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. The same review also noted reports of adverse consequences and emphasized regulatory and product-quality concerns [10].
• Manufacturing context: the recent chemistry and pharmacology review reinforces that commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter [11].
• Bottom line: delta-8 THC should be treated as a psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize [9]-[11].

THCa

• Evidence profile: important chemically and formulation-wise, but still low on direct human therapeutic evidence [12].
• What it is: THCa is the acidic precursor of THC and may represent a very large share of the THC-related content in raw plant material. The key formulation issue is that THCa decarboxylates into THC during heating and can also change over time during storage and processing [12].
• Psychoactivity: the major review source stresses that THCa itself does not produce the psychoactive effects associated with THC in humans, but the distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated [12].
• Research status: in vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].
• Bottom line: THCa is best understood as a highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa needs to account for possible conversion into THC [12].

Delta-9 THC

• Evidence profile: strongest human evidence of the psychoactive cannabinoids listed here, but also the clearest adverse-effect burden [1][13]-[15].
• What is institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while still stressing that many other uses remain uncertain or early-stage [1].
• Pain evidence: a 2022 systematic review of cannabis-based products for chronic pain found that products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but they also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13].
• Pharmacokinetics and onset: classic pharmacokinetic review literature remains useful here: inhaled THC usually produces effects within seconds to minutes, peaks roughly within 15 to 30 minutes, and tapers over a few hours; oral THC has later onset, later peak, and longer duration, which matters for both benefit and overconsumption risk [14].
• Mental-health risk: a 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings [15].
• Broader safety: institutional and review literature also describe anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns in THC-containing products [1][14][15].
• Bottom line: delta-9 THC has legitimate therapeutic relevance in some settings, but it also carries the clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15].

CBN

• Evidence profile: weak human evidence; marketing has clearly moved ahead of the data [12][16][17].
• What it is often marketed for: sleep and sedation. That reputation is widespread, but the clinical support is far thinner than the market suggests [16][17].
• Best direct review for the sleep claim: the 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN [16].
• Broader sleep literature: the 2024 updated review on cannabis and sleep concluded that overall cannabinoid sleep research still does not match the scale of real-world use, and the need for better-designed, adequately powered trials remains substantial [17].
• Chemical context: downstream cannabinoid degradation pathways matter here as well; review literature on THCa notes that THC can further degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts [12].
• Bottom line: CBN is one of the clearest examples in this field where cultural reputation is stronger than the current clinical evidence base [16][17].

CBC

• Evidence profile: emerging, intriguing, and still overwhelmingly preclinical or review-based [18][19].
• Pharmacology and therapeutic interest: the 2024 focused review on CBC argues that it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets [18].
• What the older literature shows: review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims [19].
• Safety caveat: the 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety [18].
• Bottom line: CBC belongs in the category of scientifically credible minor cannabinoids that deserve more research, not in the category of already-validated clinical actives [18][19].

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than from controlled human studies of cannabis formulations. The 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

• Evidence profile: largely review and preclinical, with useful safety literature [20]-[22].
• Potential activity: a 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but the overwhelming share of those claims comes from nonhuman or non-cannabis literature [21].
• Safety note: limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens and are important in patch-testing literature [22].
• Bottom line: limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless they are directly supported in humans [20]-[22].

Myrcene

• Evidence profile: mostly preclinical, with very limited human evidence [20][23].
• Research summary: the 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states that human studies are lacking [23].
• Interpretation caution: myrcene is often invoked in consumer language as if it were a proven sedating terpene that explains couch-lock or sleep effects. That is a stronger claim than the human evidence currently supports [20][23].
• Bottom line: myrcene is a plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23].

Caryophyllene

• Evidence profile: among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical [24].
• Why it stands out: a 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24].
• Research themes: anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions are repeatedly discussed in the review literature, but human clinical confirmation remains limited [24].
• Bottom line: beta-caryophyllene is arguably the strongest candidate for a terpene with cannabinoid-system significance, but it still should not be described as clinically proven for the outcomes commonly attributed to it [24].

Pinene

• Evidence profile: promising preclinical literature, weak human clinical confirmation [20][25].
• Brain-health framing: the 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but it also emphasized that evidence is mostly preclinical and that well-designed clinical trials are lacking [25].
• Interpretation caution: claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].
• Bottom line: pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool

• Evidence profile: similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].
• Research summary: linalool is repeatedly discussed in relation to stress, mood, and brain-health pharmacology. The 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing the lack of robust human trials [25].
• Additional literature: separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains a translational rather than definitive clinical story [26].
• Safety note: as with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22].
• Bottom line: linalool is scientifically credible as a bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene

• Evidence profile: translationally interesting, but still early [20][27].
• Scoping-review findings: a 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].
• Interpretation caution: those findings are valuable for hypothesis generation, but they do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].
• Bottom line: humulene is one of the more interesting terpene research targets in this list, but it remains far from clinically settled [27].

Terpinolene

• Evidence profile: one of the least clinically characterized terpenes in this file [20][28].
• Systematic-review findings: the 2021 terpinolene review screened 2,449 records and included 57 studies, concluding that terpinolene has a range of reported biological effects but that the evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials [28].
• Interpretation caution: even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects [20].
• Bottom line: terpinolene is biologically interesting, but among the listed terpenes it remains especially underdeveloped clinically [20][28].

Research limits and interpretation

• The evidence base is highly uneven. CBD and delta-9 THC can support the most detailed human-facing statements; the rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. One common error in cannabis writing is to let evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means the claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products [1][10][11][14].
• For THCa in particular, chemistry is destiny: storage and heating can change the actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12].

Common overstatements to avoid

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: the specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17].
• Overstatement: myrcene is a proven human sedative that reliably explains couch-lock.
  More accurate: myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23].
• Overstatement: terpenes in general have proven entourage effects in patients.
  More accurate: entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing the effective exposure [12].
• Overstatement: delta-8 THC is safe because it is hemp-derived.
  More accurate: delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical takeaways for the formulas in this document

• The most evidence-developed actives in these formulas are CBD and delta-9 THC.
• Delta-8 THC is not a trivial or purely mild ingredient; it is a psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted the same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
• The listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

References

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

RSO Sublingual Oil

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5%
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg

RSO Vape Cartridge

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%
• Format: 1 Gram cartridge

Terpene Profile (Both Products)

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene – pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

---